The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Cyclic AMP results in increased expression of ABCA1 mRNA; Cyclic AMP results in increased expression of ABCA1 protein [HCAR2 protein results in decreased abundance of Cyclic AMP] which results in decreased expression of ABCA1 protein
ADM protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]]; Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP] ADM protein results in increased abundance of Cyclic AMP; ADM results in increased abundance of Cyclic AMP
[3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Bupranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; Isoproterenol promotes the reaction [ADRB1 protein results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] ADRB1 protein affects the abundance of Cyclic AMP; ADRB1 protein polymorphism affects the abundance of Cyclic AMP ADRB1 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]
[Terbutaline results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; ADRB2 protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP] ADRB2 protein polymorphism results in increased chemical synthesis of Cyclic AMP; ADRB2 protein results in increased chemical synthesis of Cyclic AMP [Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [BRL 37344 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Isoproterenol results in increased activity of ADRB2 protein] which results in increased chemical synthesis of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metaproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Oxprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Sotalol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP] ADRB2 protein results in increased abundance of Cyclic AMP ADRB2 protein affects the abundance of Cyclic AMP
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [[SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP]; [Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [broxaterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [CGP 20712A binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Fenoterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Formoterol Fumarate binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [Isoproterenol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Salmeterol Xinafoate binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; [SR 59119A binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; [Terbutaline binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP ADRB3 protein affects the abundance of Cyclic AMP
AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP inhibits the reaction [AHR protein binds to ARNT protein]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer] 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA Cyclic AMP results in decreased expression of AHR protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]; N-(2-aminoethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased expression of AQP3 mRNA]
Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein]; Cyclic AMP affects the expression of and results in increased phosphorylation of and results in increased localization of AQP5 protein
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP
[AVP protein binds to and results in increased activity of AVPR2 protein mutant form] which results in increased abundance of Cyclic AMP; [AVP protein binds to and results in increased activity of AVPR2 protein] which results in increased abundance of Cyclic AMP AVPR2 protein results in increased abundance of Cyclic AMP
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein
Cyclic AMP results in increased activity of BRAF protein [Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased activity of BRAF protein
CALCA protein modified form results in increased abundance of Cyclic AMP; CALCA protein results in increased abundance of Cyclic AMP CALCA protein inhibits the reaction [Isoproterenol promotes the reaction [ADM protein results in increased abundance of Cyclic AMP]] Isoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]; sevoflurane inhibits the reaction [CALCA protein modified form results in increased abundance of Cyclic AMP]
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter]
CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP]
[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein; sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CCND1 protein]
CGB3 protein results in increased chemical synthesis of Cyclic AMP [Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Sphingosine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Tetradecanoylphorbol Acetate inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]
[Pentoxifylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; [Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein; Sorafenib inhibits the reaction [[Theophylline results in increased abundance of Cyclic AMP] which results in increased expression of CDKN1B protein]
Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Bicarbonates]; Cyclic AMP promotes the reaction [CFTR protein results in increased transport of Chlorides] CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]; Cyclic AMP affects the localization of and results in increased activity of CFTR protein; Nitric Oxide inhibits the reaction [CFTR protein promotes the reaction [Cyclic AMP results in increased transport of Chlorine]]; Nocodazole inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein]; Primaquine inhibits the reaction [Cyclic AMP affects the localization of and results in increased activity of CFTR protein] Cyclic AMP results in increased activity of CFTR protein Genistein promotes the reaction [Cyclic AMP results in increased activity of CFTR protein mutant form]
[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA CGA protein affects the secretion of Cyclic AMP CGA protein results in increased abundance of Cyclic AMP [CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; [CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP]; Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]; DDT inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] which results in increased abundance of Cyclic AMP]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA
[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; [Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of CREB1 protein; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer]
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP] CRH protein inhibits the reaction [[Cholera Toxin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Cholera Toxin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Manganese results in increased chemical synthesis of Cyclic AMP]; Sphingosine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]; Staurosporine inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Cyclic AMP]]
[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]
CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; CSK protein promotes the reaction [Terbutaline results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]]
Cyclic AMP results in increased expression of CYP11A1 mRNA Cyclic AMP results in increased expression of CYP11A1 mRNA; Cyclic AMP results in increased expression of CYP11A1 protein myricetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of CYP11A1 mRNA]
[acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [acetyl methyl tetramethyl tetralin co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in decreased activity of CYP17A1 protein; [galaxolide co-treated with Cyclic AMP] results in increased activity of CYP17A1 protein Cyclic AMP results in increased expression of CYP17A1 mRNA
Cyclic AMP results in increased expression of CYP19A1 mRNA; Cyclic AMP results in increased expression of CYP19A1 protein [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of CYP19A1 mRNA]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA
Cyclic AMP results in increased expression of CYP1B1 mRNA; Cyclic AMP results in increased expression of CYP1B1 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Kynurenine co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [Tryptophan co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA AHR protein promotes the reaction [Cyclic AMP results in increased expression of CYP1B1 mRNA]; Cyclic AMP promotes the reaction [AHR protein binds to CYP1B1 enhancer]; Cyclic AMP promotes the reaction [CREB1 protein binds to CYP1B1 enhancer]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA
A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP] [SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP; A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]; SCH 23390 inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Spiperone inhibits the reaction [A 86929 promotes the reaction [DRD1 protein results in increased chemical synthesis of Cyclic AMP]]
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] [quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP; CCKBR protein affects the reaction [[quinelorane binds to and results in increased activity of DRD2 protein] which results in decreased abundance of Cyclic AMP]
[3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine binds to and results in decreased activity of DRD4 protein] inhibits the reaction [Naloxone results in increased abundance of Cyclic AMP]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA
[Cyclic AMP results in increased phosphorylation of CARM1 protein] promotes the reaction [CARM1 protein binds to ESR1 protein]; CARM1 protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; CREBBP protein promotes the reaction [Cyclic AMP results in increased activity of ESR1 protein]; Cyclic AMP promotes the reaction [CARM1 protein binds to ESR1 protein]; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Cyclic AMP results in increased activity of ESR1 protein]
ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]; Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]]; ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [C186 65 binds to and results in increased activity of F2R protein] which results in decreased chemical synthesis of Cyclic AMP
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] which results in decreased chemical synthesis of Cyclic AMP
myricetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of FDX1 mRNA]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA
[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of FOXO1 mRNA] FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; 4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenol inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA; fulvestrant inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Methoxychlor inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP] FSHB protein results in increased secretion of Cyclic AMP NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]] [FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]
[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; [FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP; Benzo(a)pyrene inhibits the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[CGA protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; Dichlorodiphenyl Dichloroethylene promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]; o,p'-DDT promotes the reaction [[FSHB protein results in increased activity of FSHR protein] which results in increased abundance of Cyclic AMP]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA
[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of G6PC1 mRNA] [Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP GCG protein results in increased chemical synthesis of Cyclic AMP Dietary Fats promotes the reaction [GCG protein results in increased chemical synthesis of Cyclic AMP]; Niclosamide inhibits the reaction [GCG protein results in increased abundance of Cyclic AMP] [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP
3,9-bis((ethylthio)methyl)-K-252a inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein; [GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; [GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium; Mazindol inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]; vanoxerine inhibits the reaction [[GDNF protein co-treated with Cyclic AMP] results in increased susceptibility to 1-Methyl-4-phenylpyridinium]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA
[GH-RH(1-29), desaminotyrosyl(1)-ornithyl(12,21)-alpha-aminobutryic acid(15)-norleucyl(27)-aspartyl(28)-agmatine(29)- binds to and results in increased activity of GHRH protein] which results in increased abundance of Cyclic AMP
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA
[GCG protein modified form binds to and results in increased activity of GLP1R protein] which results in increased abundance of Cyclic AMP [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [ARRB2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]; [[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] which affects the localization of ARRB2 protein; [GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP
[[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP
[[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP
[[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP] [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Cyclic AMP [Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; [Lithocholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA
[[GCG protein binds to and results in increased activity of GLP1R protein] which results in increased chemical synthesis of Cyclic AMP] promotes the reaction [GRK2 protein binds to GLP1R protein]
[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] HCAR2 protein results in decreased abundance of Cyclic AMP
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA
1-Methyl-3-isobutylxanthine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]; HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in decreased abundance of Cyclic AMP]]
HRH2 protein results in increased abundance of Cyclic AMP [Cimetidine binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cyclic AMP; [Dimaprit binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; [Histamine binds to and results in increased activity of HRH2 protein] which results in increased abundance of Cyclic AMP; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in decreased activity of HRH2 protein] which results in decreased abundance of Cimetidine]; Burimamide inhibits the reaction [[Cyclic AMP binds to and results in increased activity of HRH2 protein] which results in increased abundance of Histamine]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12A protein]; Cyclic AMP promotes the reaction [[Histamine results in increased activity of HRH2 protein] which results in decreased expression of IL12B protein]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]
HTR7 results in increased abundance of Cyclic AMP [3,N-dimethyl-N-(1-methyl-3-(4-methylpiperidin-1-yl)propyl)benzenesulfonamide binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [5-carboxamidotryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Clozapine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] which results in decreased abundance of Cyclic AMP; [Methoxydimethyltryptamines binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Mianserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Ritanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Serotonin binds to and results in increased activity of HTR7 protein] which results in increased abundance of Cyclic AMP; [Spiperone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [volinanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of IER3 mRNA] IER3 protein affects the susceptibility to Cyclic AMP [[IER3 protein affects the chemical synthesis of Reactive Oxygen Species] which results in increased expression of GNAI2] which results in decreased chemical synthesis of Cyclic AMP; IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]; Pertussis Toxin affects the reaction [IER3 protein affects the reaction [Isoproterenol results in increased abundance of Cyclic AMP]]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased abundance of Kynurenine; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of AHR mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1A1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of CYP1B1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 mRNA; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of IDO1 protein; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]
2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
[Metformin co-treated with Cyclic AMP] results in decreased expression of IL15RA mRNA; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]; Ibuprofen inhibits the reaction [IL1B protein results in increased abundance of Cyclic AMP]; KT 5720 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; KT 5823 inhibits the reaction [Dipyridamole promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]]; Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP] Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of CRP mRNA]; Cyclic AMP inhibits the reaction [IL1B protein results in increased expression of HP mRNA]; Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]
Cyclic AMP promotes the reaction [IL1B protein results in increased expression of IL1RN mRNA]; Cyclic AMP promotes the reaction [Metformin results in increased expression of IL1RN mRNA]; Metformin promotes the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA]
IL4 protein results in increased chemical synthesis of Cyclic AMP Ketoconazole inhibits the reaction [IL4 protein results in increased chemical synthesis of Cyclic AMP]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA
[Theophylline co-treated with INS1 protein] results in decreased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with Norepinephrine] results in increased abundance of Cyclic AMP]; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA
LEP protein results in increased abundance of Cyclic AMP 3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrile inhibits the reaction [Cyclic AMP analog results in increased expression of LEP mRNA]
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; [Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA; [LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP; CRH protein inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP]; Masoprocol inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[LHB protein co-treated with Guanylyl Imidodiphosphate] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [LHB protein results in increased chemical synthesis of Cyclic AMP] LHB protein affects the secretion of Cyclic AMP [LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [LHB protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Cyclic AMP; DDT inhibits the reaction [LHB protein results in increased abundance of Cyclic AMP]
[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP; ESR1 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; ESR2 protein promotes the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[CGB3 protein results in increased activity of LHCGR protein] which results in increased abundance of Cyclic AMP] [ESR2 gene mutant form results in decreased expression of LHCGR protein] inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein
Cyclic AMP results in increased phosphorylation of NDUFB11 protein Zalcitabine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]; Zidovudine inhibits the reaction [Cyclic AMP results in increased phosphorylation of NDUFB11 protein]
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA; [Isoproterenol results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Cyclic AMP results in increased expression of NGF mRNA
NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Cyclic AMP]]
Cyclic AMP results in increased activity of OAT protein Deoxyglucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Dihydroxyacetone inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Fructose inhibits the reaction [Cyclic AMP results in increased expression of OAT mRNA]; Galactose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glucose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Glycerol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Inositol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Mannose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Rhamnose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Sorbose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]; Xylitol inhibits the reaction [Cyclic AMP results in increased activity of OAT protein]
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [[Naloxone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [[Naltrexone binds to and results in decreased activity of OPRM1 protein] which co-treated with Morphine] results in increased expression of Cyclic AMP; [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [clocinnamox binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP; [nalmefene binds to and results in decreased activity of OPRM1 protein] which results in increased expression of Cyclic AMP
[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP; octanoic acid promotes the reaction [[pelargonic acid results in increased activity of OR51A5 protein] which results in increased abundance of Cyclic AMP]
[[Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP] which results in increased expression of EGR1 mRNA; [Eugenol binds to and results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP; [Eugenol results in increased activity of OR5D18 protein] which results in increased abundance of Cyclic AMP
[citronellal results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP [[GNAL protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP; [[GNAS protein results in increased susceptibility to citronellal] which results in increased activity of OR6E1 protein] which results in increased abundance of Cyclic AMP
Cyclic AMP results in increased expression of PCK1 mRNA [Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein; [Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [[Oleic Acid co-treated with Palmitic Acid] inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]; ochratoxin A inhibits the reaction [Cyclic AMP results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PCK1 mRNA]
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]
[[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; [S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP [Bresol results in decreased activity of PDE4B protein] which results in increased abundance of Cyclic AMP; Cyclic AMP inhibits the reaction [DISC1 protein binds to PDE4B protein]
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7A protein results in increased hydrolysis of Cyclic AMP]
PDE7B protein results in increased hydrolysis of Cyclic AMP 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; E 4021 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; vinpocetine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP] 1-Methyl-3-isobutylxanthine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; Papaverine inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]; SCH 51866 inhibits the reaction [PDE7B protein results in increased hydrolysis of Cyclic AMP]
Dipyridamole inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8A protein results in increased metabolism of Cyclic AMP] PDE8A protein results in increased hydrolysis of Cyclic AMP Dipyridamole inhibits the reaction [PDE8A protein results in increased hydrolysis of Cyclic AMP]
9-(2-hydroxy-3-nonyl)adenine inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; E 4021 inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]; Sildenafil Citrate inhibits the reaction [PDE8B protein results in increased metabolism of Cyclic AMP]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP]; tubacin affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; tubastatin A affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]; W 7 affects the reaction [PDK1 protein affects the abundance of Cyclic AMP]
Cyclic AMP inhibits the reaction [[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] inhibits the reaction [CGA protein results in increased expression of PGR mRNA]]
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]
Cyclic AMP results in increased expression of PLA2G4A mRNA; Cyclic AMP results in increased expression of PLA2G4A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of PLA2G4A protein]
[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP; INS1 protein inhibits the reaction [[Theophylline co-treated with POMC protein] results in increased abundance of Cyclic AMP] POMC protein modified form results in increased abundance of Cyclic AMP Quercetin analog inhibits the reaction [POMC protein modified form results in increased abundance of Cyclic AMP]
Cyclic AMP promotes the reaction [PPARGC1A protein binds to CYP2A5 promoter]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in decreased expression of IL15RA mRNA]; PPARGC1A mutant form inhibits the reaction [Cyclic AMP results in increased expression of IL1RN mRNA] [Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; [Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Dexamethasone co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased expression of PPARGC1A mRNA]; Fatty Acids analog inhibits the reaction [[Glucagon co-treated with Cyclic AMP] results in increased phosphorylation of PPARGC1A protein] Cyclic AMP results in increased expression of PPARGC1A mRNA
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PKIA protein]; [PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]
[PRKACB protein mutant form affects the susceptibility to Cyclic AMP] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]
[Atrazine results in increased abundance of Cyclic AMP] which results in increased secretion of PRL protein 2-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; 4-hydroxyestradiol promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; IFNG protein promotes the reaction [Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]]; Kynurenine promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA]; Tryptophan promotes the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of PRL mRNA] Cyclic AMP results in increased secretion of PRL protein
[5-hydroxyindomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [Indomethacin binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP; [sulindac sulfide binds to PTGDR2 protein] which results in decreased abundance of Cyclic AMP
[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP]
[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP]
[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP; GNAS protein promotes the reaction [[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Cyclic AMP]
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Cyclic AMP]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein
Cyclic AMP affects the expression of SLC2A5 mRNA [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein [Fructose results in increased abundance of Cyclic AMP] which results in increased stability of SLC2A5 mRNA
Nitric Oxide inhibits the reaction [SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]]; SLC4A2 protein promotes the reaction [Cyclic AMP results in increased transport of Bicarbonates]
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]
[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein; Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; Diltiazem promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Isradipine promotes the reaction [Cyclic AMP results in increased expression of STAR protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]]; myricetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; N-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Cyclic AMP co-treated with Verapamil] results in increased expression of STAR protein]; Nifedipine promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR mRNA]; perfluorododecanoic acid inhibits the reaction [Cyclic AMP results in increased expression of STAR protein]; quercetin pentaacetate promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Quercetin promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR mRNA]; Verapamil promotes the reaction [Cyclic AMP results in increased expression of STAR protein] Cyclic AMP results in increased expression of STAR mRNA; Cyclic AMP results in increased expression of STAR protein
[Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP [3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [3-tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-chloro-2-(imidazolin-2-yl)isoindoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [4-phenyl-1,2,3,4-tetrahydroisoquinoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [5-Methoxytryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [6-nitroquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Antazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [BE 2254 results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [cirazoline results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Clonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [efaroxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Guanabenz results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [harman results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Histamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Idazoxan results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Methoxydimethyltryptamines results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [moxonidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [N-methylquipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [O-methyltyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Octopamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [phenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Quipazine analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [rilmenidine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tranylcypromine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [tryptamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tryptamines analog results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP; [Tyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA]; [IFNG protein co-treated with [Medroxyprogesterone Acetate co-treated with Cyclic AMP]] results in increased expression of TDO2 mRNA
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA
CARM1 protein promotes the reaction [Cyclic AMP results in increased expression of TFF1 mRNA]; Cyclic AMP promotes the reaction [CARM1 protein binds to TFF1 promoter]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of E2F2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FOXM1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of FZD10 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of GLI1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HES3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of HOXB1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of INHBE mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of LEF1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in decreased expression of TERT mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of CNTN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of DLG4 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GABRA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GFAP mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIA2 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN1 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of GRIN2B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of MAP2 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of RBFOX3 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of S100B protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SCN2A mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A6 mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SLC17A7 protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN mRNA; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of SYN protein; [BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein
Cyclic AMP results in decreased expression of TNF protein Cyclic AMP inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] [[S-Adenosylmethionine inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]] which results in increased abundance of Cyclic AMP] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Cyclic AMP results in increased expression of TRPV4 mRNA; Cyclic AMP results in increased expression of TRPV4 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cyclic AMP results in increased expression of TRPV4 protein]
[Cobalt binds to dipyrido(3,2-a-2',3'-c)phenazine binds to N-(2-hydroxybenzyl)glycine analog] inhibits the reaction [TSHB protein results in increased abundance of Cyclic AMP]; [TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]]
[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP; bisphenol A inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Diethylstilbestrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; Estradiol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]; resveratrol inhibits the reaction [[TSHB protein results in increased activity of TSHR protein] which results in increased abundance of Cyclic AMP]; TSHB protein inhibits the reaction [NCGC 00229600 inhibits the reaction [TSHR protein results in increased abundance of Cyclic AMP]]
[BDNF protein co-treated with GDNF protein co-treated with Cyclic AMP co-treated with TGFB3 protein co-treated with Ascorbic Acid] results in increased expression of TUBB3 protein
[VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP alpha-hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Endrin inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP]; Hexachlorocyclohexane inhibits the reaction [VIP protein results in increased abundance of Cyclic AMP] VIP protein results in increased abundance of Cyclic AMP; VIP results in increased abundance of Cyclic AMP
[ADCYAP1 protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP; [VIP protein binds to VIPR2 protein] which results in increased abundance of Cyclic AMP
WNT5A protein affects the reaction [[Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP] which results in increased expression of SOD2 mRNA]; WNT5A protein affects the reaction [Medroxyprogesterone Acetate results in increased abundance of Cyclic AMP]
ABCC4 protein results in increased export of Cyclic GMP ABCC4 protein results in increased transport of Cyclic GMP daidzein inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Dipyridamole inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; hesperetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; naringenin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Probenecid inhibits the reaction [ABCC4 protein results in increased transport of Cyclic GMP]; Quercetin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; resveratrol inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]; Silymarin inhibits the reaction [ABCC4 protein results in increased export of Cyclic GMP]
AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; AGT protein modified form inhibits the reaction [Streptozocin results in decreased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]] AGT protein modified form results in increased abundance of Cyclic GMP
[bradykinin, Leu(8)-des-Arg(9)- results in decreased activity of BDKRB1 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]
EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [HPH1 gene mutant form results in decreased abundance of Cyclic GMP]
GCH1 protein affects the abundance of Cyclic GMP GCH1 gene mutant form results in increased abundance of Cyclic GMP CAT protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]; EPO protein inhibits the reaction [GCH1 gene mutant form results in increased abundance of Cyclic GMP]
[GUCY1A1 protein binds to GUCY1B1 protein] which results in increased chemical synthesis of Cyclic GMP; GUCY1A1 protein mutant form inhibits the reaction [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole results in increased abundance of Cyclic GMP]; GUCY1A1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased abundance of Cyclic GMP] GUCY1A1 gene mutant form results in increased abundance of Cyclic GMP
Halothane inhibits the reaction [IL1B protein results in increased abundance of Cyclic GMP] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Cyclic GMP]
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein] Cyclic GMP results in decreased phosphorylation of MAP2K1 protein
Cyclic GMP results in decreased phosphorylation of MAP2K2 protein Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein]
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]; Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K2 protein] NPPA protein results in increased abundance of Cyclic GMP AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]; Puromycin Aminonucleoside inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]; vinpocetine inhibits the reaction [AGT protein inhibits the reaction [NPPA protein results in increased abundance of Cyclic GMP]]
NPPC protein results in increased chemical synthesis of Cyclic GMP NPPC protein results in increased abundance of Cyclic GMP Ammonia inhibits the reaction [NPPC protein results in increased chemical synthesis of Cyclic GMP]; Fluoroacetates inhibits the reaction [NPPC protein results in increased abundance of Cyclic GMP]
Cyclic AMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]; Cyclic GMP inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic AMP]; Dipyridamole inhibits the reaction [PDE10A protein results in increased hydrolysis of Cyclic GMP]
1-Methyl-3-isobutylxanthine inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; Dipyridamole inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]; zaprinast inhibits the reaction [PDE11A protein results in increased hydrolysis of Cyclic GMP]
PDE9A protein results in increased hydrolysis of Cyclic GMP zaprinast inhibits the reaction [PDE9A protein results in increased hydrolysis of Cyclic GMP]
7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; KMUP 1 inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]; zaprinast inhibits the reaction [TNF protein results in decreased abundance of Cyclic GMP]
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [VEGFA protein results in increased abundance of Cyclic GMP]
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein] SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol]
7-methylguanosine 5'-diphosphate analog binds to EIF4E protein 7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine-5'-monophosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Quinolones inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Sulfonamides inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]
7-methylguanosine triphosphate inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; 7-methylguanosine triphosphate inhibits the reaction [RNA Caps binds to EIF4E protein]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]; Sirolimus promotes the reaction [EIF4EBP1 protein binds to 7-methylguanosine triphosphate]
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]; Sirolimus inhibits the reaction [EIF4G1 protein binds to 7-methylguanosine triphosphate]
Mevalonic Acid inhibits the reaction [mevastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]]; pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of ABCA1 protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased expression of BCL2L11 protein BCL2L11 protein results in increased susceptibility to 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein mutant form
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of and results in increased activity of CREB1 protein 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased phosphorylation of CREB1 protein
NR1H2 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]
NR1H3 gene mutant form inhibits the reaction [pitavastatin inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in increased export of Cholesterol]]
8-((4-chlorophenyl)thio)cyclic-3',5'-AMP inhibits the reaction [RHOA protein binds to RTKN protein] 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP results in decreased activity of RHOA protein
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-AMP affects the splicing of SNAP25 exon]
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 mRNA; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of ALOX15 protein
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of CEBPB protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein 8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of FABP4 protein]
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphorothioate inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased expression of PPARG protein]
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; [calyculin A co-treated with Okadaic Acid] inhibits the reaction [2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein]]; KT 5823 inhibits the reaction [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP promotes the reaction [PRKG1 protein binds to and results in increased phosphorylation of ARHGEF17 protein]]; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]; Y 27632 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of ARHGEF17 protein] 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein; 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased expression of PRKG1 protein alternative form 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased activity of PRKG1 protein [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein alternative form] inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]
[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] promotes the reaction [ARHGEF17 protein results in increased activity of RHOA protein]; [8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein; KT 5823 inhibits the reaction [[8-((4-chlorophenyl)thio)cyclic-3',5'-GMP co-treated with PRKG1 protein] results in increased activity of RHOA protein]
8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in increased phosphorylation of VASP protein 8-((4-chlorophenyl)thio)cyclic-3',5'-GMP results in decreased phosphorylation of VASP protein
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADGRF5 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AGR2 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of AKAP7 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ANGPT1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of ANXA8 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of AR mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of BAX [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of BAX protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]]; [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CCL2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CCL2 protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEACAM6 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CLIC3 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CLIC3 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL15A1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL4A6 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of COL7A1 mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [CRH protein inhibits the reaction [CGB3 protein results in increased chemical synthesis of Testosterone]]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of CST6 mRNA
2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 protein bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP11A1 protein]
bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA]; Mitotane affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11B1 mRNA]
[4-nitro-3-phenylphenol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of CYP17A1 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; 2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]]; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]; Triiodothyronine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 protein]
[vinclozolin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Atrazine promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA]; bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; formestane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein]; Methoxychlor inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of CYP19A1 protein] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP19A1 protein
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP1B1 protein
7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of DIO2 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein Acetylcysteine inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]; Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO2 protein]]
Acetylcysteine inhibits the reaction [[Hydrogen Peroxide co-treated with Sodium Selenite] promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]]; Hydrogen Peroxide promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased activity of DIO3 protein]
EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of EMP2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EMP2 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of EZH2 protein [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in decreased expression of EZH2 protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FDXR protein]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of FLOT1 mRNA
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 mRNA]; Hydrogen Peroxide inhibits the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of FOXO1 protein]
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] inhibits the reaction [Hydrogen Peroxide results in increased expression of FOXO3 protein]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of FOXO3 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB protein Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FSHB mRNA]
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of GADD45A protein
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of GFAP mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA]
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HMOX1 mRNA]
4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of and results in increased activity of HSD11B1 protein; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of HSD11B1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD11B2 mRNA [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B2 protein
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [bisphenol A results in decreased expression of HSD17B1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B1 mRNA
bisphenol A inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA] [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD17B2 protein
2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of HSD3B1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 protein
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA [4-nitro-3-cresol co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of HSD3B2 protein; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B2 mRNA]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
1-Butanol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; 4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein; Dexamethasone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of IGFBP1 protein]; Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 protein 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of IGFBP1 protein
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased secretion of CCL2 protein]] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IL1A mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of IL6 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of KCTD12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCTD12 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of KCTD12 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LAMA3 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LAMP3 mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]] LEP protein results in decreased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate
LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB protein Tetrachlorodibenzodioxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LHB mRNA]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of LIF mRNA [NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LIMCH1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LMO3 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of LOXL1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPCAT1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of LPL mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased activity of LPL protein
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LXN mRNA
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK1 protein [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK1 protein]
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased activity of MAPK3 protein [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of MAPK3 mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased phosphorylation of MAPK3 protein]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of MC2R mRNA [20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of MUC1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of NCF2 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of NKX2-1 mRNA
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of NR3C1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of ZNF486 mRNA]; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR3C2 mRNA [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of NR3C2 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A1 protein 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of NR4A1 mRNA
[20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] promotes the reaction [NR5A1 protein binds to MC2R promoter]; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] affects the expression of HSD17B2 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Estradiol; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Testosterone; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP11B1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP17A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP19A1 mRNA; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of CYP21A1 mRNA; [NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of PDLIM4 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PECAM1 mRNA
[8-Bromo Cyclic Adenosine Monophosphate co-treated with Progesterone co-treated with Estradiol] affects the expression of and affects the phosphorylation of PGR protein 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PGR protein
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of and results in increased activity of PLD1 protein; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PPARG mRNA 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA]
[PRKACB protein mutant form results in increased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate analog] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]
[PRKACB protein mutant form results in increased susceptibility to 8-Bromo Cyclic Adenosine Monophosphate analog] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRKAR2B mRNA [monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of PRKAR2B protein
1-Butanol inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Dexamethasone] results in increased expression of PRL mRNA; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein; EZH2 mutant form inhibits the reaction [[8-Bromo Cyclic Adenosine Monophosphate co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA]; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased secretion of PRL protein]; PLD1 protein affects the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; Tobacco Smoke Pollution inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA] 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL protein 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRL mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of PRL protein 8-Bromo Cyclic Adenosine Monophosphate results in increased secretion of PRL protein
8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [PTGS2 co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of VEGFA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ROR1 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of ROR1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of SERPINE1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SFTPB mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SFTPC mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC25A36 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC39A8 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLC6A14 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of SLCO4C1 mRNA
[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA; [Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 protein; FOXO1 protein affects the reaction [[Medroxyprogesterone Acetate co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of SOD2 mRNA]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Glucose results in increased secretion of SPP1 protein]] 8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of SPP1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; bifenthrin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; Mitotane inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; T-2 Toxin inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA] 2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [sodium arsenite results in increased expression of STAR mRNA]; 8-Bromo Cyclic Adenosine Monophosphate promotes the reaction [sodium arsenite results in increased expression of STAR protein]; Anisomycin promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Dantrolene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Hydrocarbons, Chlorinated inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; Ryanodine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; sodium arsenite promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; sodium arsenite promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]]; Triiodothyronine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB2 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TGFB3 mRNA
THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP11A1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of CYP17A1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of HSD3B1 mRNA]]; THRA mutant form inhibits the reaction [2,2',4,4'-tetrahydroxybenzophenone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TMC5 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNC mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNC mRNA
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TNFAIP3 mRNA [Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNFAIP3 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TNFSF4 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53; 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TP53 protein
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of TPM1 mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TRIM2 mRNA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of TRIM2 mRNA
[PTGS2 co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of VEGFA 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of VEGFA mRNA
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of WIF1 mRNA
8-Bromo Cyclic Adenosine Monophosphate results in decreased expression of WNT4 mRNA [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA]
[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in decreased expression of WNT5B mRNA
8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]]
8-bromocyclic GMP results in increased expression of COX4I1 protein tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of COX4I1 protein]
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein] 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of EDN1 protein]
8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]
8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A mRNA]; 8-bromocyclic GMP inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein]
8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [8-bromocyclic GMP promotes the reaction [IL1B protein results in increased abundance of Nitrites]]
8-bromocyclic GMP results in increased expression of IL4 mRNA Cyclosporine inhibits the reaction [8-bromocyclic GMP results in increased expression of IL4 mRNA]
8-bromocyclic GMP results in increased expression of NDUFB8 protein tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NDUFB8 protein]
8-bromocyclic GMP results in increased expression of NRF1 mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of NRF1 mRNA]
[1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein; [1-Methyl-3-isobutylxanthine co-treated with 8-bromocyclic GMP] results in increased expression of PDE5A protein modified form
8-bromocyclic GMP results in increased expression of PPARGC1A mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of PPARGC1A mRNA]
8-bromocyclic GMP results in increased expression of PRKG1 protein [8-bromocyclic GMP co-treated with PRKG1 protein co-treated with ARHGEF17 protein] results in increased activity of SRF protein
8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]; Dinitrochlorobenzene inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [8-bromocyclic GMP inhibits the reaction [Glucose results in increased secretion of SPP1 protein]]
8-bromocyclic GMP results in increased expression of TFAM mRNA tin protoporphyrin IX inhibits the reaction [8-bromocyclic GMP results in increased expression of TFAM mRNA]
8-bromocyclic GMP inhibits the reaction [[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]; 8-bromocyclic GMP inhibits the reaction [[EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased activity of TH protein]
8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]; KT 5823 inhibits the reaction [8-bromocyclic GMP inhibits the reaction [TNF protein results in increased activity of CASP3 protein]]
8-bromocyclic GMP inhibits the reaction [1-oleoyl-2-acetylglycerol results in increased activity of TRPC6 protein] 8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein KT 5823 inhibits the reaction [8-bromocyclic GMP results in increased phosphorylation of TRPC6 protein]
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A]
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]
[2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]
adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]]
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate
adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate
estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein] Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form
Adenosine Diphosphate results in decreased secretion of ALB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein]
PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Adenosine Diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]
Adenosine Diphosphate results in increased expression of CD40LG protein clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]
Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein]
Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]
CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]]
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]]
Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein]
F2 protein results in increased abundance of Adenosine Diphosphate Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]
Adenosine Diphosphate results in decreased secretion of FGB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein]
Adenosine Diphosphate results in increased secretion of FGG protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein]
Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
Adenosine Diphosphate results in increased expression of IL6 protein MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein]
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]
Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]
P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate P2RY12 protein results in increased susceptibility to Adenosine Diphosphate Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate] P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]
Adenosine Diphosphate results in increased secretion of PDGFB protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein]
Adenosine Diphosphate results in increased secretion of PF4 protein silidianin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; Silybin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; silychristin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in increased abundance of Adenosine Diphosphate]
Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein]
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein]
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]
Adenosine Diphosphate results in increased phosphorylation of VASP protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein]
ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose]
Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein 2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]]; Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; Glutathione inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium]
[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate
[Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCC1 protein
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat] Adenosine Triphosphate affects the activity of ABCC2 protein [Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide] ABCC2 protein affects the metabolism of Adenosine Triphosphate Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine]
[Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]]
ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate]
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] ABL1 protein mutant form results in increased chemical synthesis of Adenosine Triphosphate
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]
Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein]
Adenosine Triphosphate results in decreased activity of AKT1 protein Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein]
ALK protein binds to Adenosine Triphosphate [ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]
ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]
[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]
Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]
Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein Adenosine Triphosphate results in increased phosphorylation of ATP7B protein
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein]
[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
Adenosine Triphosphate results in increased secretion of CALCA protein Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]
Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of CASP1 protein modified form]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]
Adenosine Triphosphate results in increased expression of CASP3 Adenosine Triphosphate inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein] Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein]
Adenosine Triphosphate results in increased secretion of CCL3 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein]
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein] Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]
[Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate
[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate]
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]]
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]]
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein]
Adenosine Triphosphate results in increased activity of CTSB protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein]
Adenosine Triphosphate results in increased secretion of CXCL2 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein]
DMD gene mutant form results in increased secretion of Adenosine Triphosphate Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate]
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]]
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]]
Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]
ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate]
2,4,3',5'-tetramethoxystilbene inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; [RWJ-56110 co-treated with 2,4,3',5'-tetramethoxystilbene] inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; Resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate] F2 protein results in increased transport of Adenosine Triphosphate STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate]
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate]
FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]
Adenosine Triphosphate results in increased expression of FOS mRNA ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] [Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]
Adenosine Triphosphate results in increased expression of FSCN1 mRNA Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA]
Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein] NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]]
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein]
[GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 protein
HMGB1 protein affects the chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; Adenosine Triphosphate promotes the reaction [fullerene C60 results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [graphene oxide results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Nanotubes, Carbon results in increased secretion of HMGB1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of HMOX1 protein]]
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein]
bisindolylmaleimide I inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; resveratrol inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]
Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]
[Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL18 protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] Adenosine Triphosphate results in increased secretion of IL18 protein 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; Enzyme Inhibitors inhibits the reaction [IL1B protein results in decreased abundance of Adenosine Triphosphate]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]] Adenosine Triphosphate results in increased secretion of IL1B protein (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Ibuprofen inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and affects the cleavage of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; zinc chloride inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]] 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein; Apigenin inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; dapansutrile inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; L 709049 inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; MitoTEMPO inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein]; NF157 compound inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]] [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; MRS 2211 inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]
Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein] Adenosine Triphosphate results in increased secretion of INS1 protein [[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]
[ammonium ferrous sulfate results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; [chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; INS protein inhibits the reaction [Acetaminophen results in decreased abundance of Adenosine Triphosphate]; Mannose inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]; Phloretin inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA]
Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein]
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased abundance of Adenosine Triphosphate; [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate KCND2 protein results in increased abundance of Adenosine Triphosphate
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] KCNJ11 protein mutant form results in decreased susceptibility to Adenosine Triphosphate
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] KCNJ8 protein mutant form results in decreased susceptibility to Adenosine Triphosphate
Adenosine Triphosphate inhibits the reaction [zinc chloride results in decreased activity of KIF5A protein]; Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]; Egtazic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]]
[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK1 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK3 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK3 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]
[annonacin results in decreased abundance of Adenosine Triphosphate] which affects the localization of MAPT protein MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of Adenosine Triphosphate]
MFN2 results in decreased susceptibility to Adenosine Triphosphate deficiency MFN2 protein inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein results in increased chemical synthesis of Adenosine Triphosphate
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of MIR219A1 mRNA; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]
[[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate MIR23B mRNA results in decreased abundance of Adenosine Triphosphate
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA]
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; SB 3CT compound inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; wortmannin inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of MMP9 protein] Adenosine Triphosphate results in increased secretion of MMP9 protein
MVK protein results in increased hydrolysis of Adenosine Triphosphate 3,3-dimethylallyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; dolichol monophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; Farnesol inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; farnesyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranyl diphosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranylgeranyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; isopentenyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]
[Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased activity of NADSYN1 protein; [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] NCS1 protein results in increased susceptibility to Adenosine Triphosphate
Adenosine Triphosphate affects the localization of NFATC1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate affects the localization of NFATC1 protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of NFE2L2 protein]]
Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; prim-O-glucosylcimifugin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] 2-(1,3-benzodioxol-5-yl)-N-(5-methyl-4-(1-(2-methylbenzoyl)-2,3-dihydroindol-5-yl)-1,3-thiazol-2-yl)acetamide inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with Resveratrol] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; SR18292 inhibits the reaction [malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein] [Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide]
Adenosine Triphosphate affects the reaction [Alcohols affects the phosphorylation of NOS3 protein]; Adenosine Triphosphate inhibits the reaction [Alcohols results in decreased expression of NOS3 protein]
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein]
geldanamycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; herbimycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1] ATP binds to P2rx1 protein
1-amino-4-(3-(4,6-dichloro(1,3,5)triazine-2-ylamino)phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Acetylcysteine inhibits the reaction [Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Cadmium Chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cobaltous chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Copper promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cupric chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Dithiothreitol inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercuric Chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; methyl methanethiosulfonate inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; methyl methanethiosulfonate inhibits the reaction [Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; myxothiazol promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; nickel chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; palladium chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; zinc chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein] ATP affects activity of rat P2x2 receptor in transfected glial cells P2RX2 protein affects the susceptibility to Adenosine Triphosphate
Eugenol inhibits the reaction [P2RX3 protein affects the activity of Adenosine Triphosphate] Adenosine Triphosphate results in increased activity of P2RX3 protein
[Cadmium co-treated with Zinc] promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [Mercury co-treated with Copper] inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cadmium promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cobalt promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]]; Mercury inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 mRNA; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Ivermectin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein; Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein; AZ 11645373 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; calmidazolium inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein]; ZINC58368839 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein] P2RX7 protein results in increased susceptibility to Adenosine Triphosphate Adenosine Triphosphate results in increased expression of P2RX7 protein P2RX7 gene mutant form results in decreased susceptibility to Adenosine Triphosphate 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]
[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium] [N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium] Adenosine Triphosphate affects the activity of P2RY1 protein
MRS 2211 inhibits the reaction [P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium [Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium Adenosine Triphosphate affects the activity of P2RY2 protein
[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium]
N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea inhibits the reaction [P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]
Adenosine Triphosphate results in decreased activity of PANX1 protein Carbenoxolone inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]; Probenecid inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]
PARP1 mutant form inhibits the reaction [Cadmium results in decreased abundance of Adenosine Triphosphate] PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate]; PARP1 protein affects the reaction [Zinc results in decreased abundance of Adenosine Triphosphate] Adenosine Triphosphate results in increased expression of PARP1 protein
[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium]
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]; Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]]
[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PML protein; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased abundance of Reactive Oxygen Species]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate; PPARG protein results in decreased abundance of Adenosine Triphosphate
[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] inhibits the reaction [PPARGC1A protein binds to NFE2L2 protein]]; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PPARGC1A protein]
Adenosine Triphosphate binds to and affects the folding of PPP5C protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Adenosine Triphosphate]
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; malvidin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; neoisoliquiritin affects the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PYCARD gene mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of G(M3) Ganglioside]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin; Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4]
[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein; [mitochondrial uncoupler BAM15 co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; Resveratrol promotes the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein]; S-Nitrosoglutathione promotes the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]
Adenosine Triphosphate results in increased expression of and results in increased secretion of S100A4 protein; Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein] Adenosine Triphosphate results in increased expression of S100A4 mRNA
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]
Adenosine Triphosphate results in increased secretion of SFTPB protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPB protein]
Adenosine Triphosphate results in increased secretion of SFTPC protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPC protein]
[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] [STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein
[SLC46A1 protein results in increased susceptibility to N-((5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-6-yl)propyl)thiophen-2-yl)carbonyl)glutamic acid] which results in decreased chemical synthesis of Adenosine Triphosphate
GW8510 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]; SB 216763 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]
SOD2 protein affects the chemical synthesis of Adenosine Triphosphate SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate]
Adenosine Triphosphate inhibits the reaction [Edetic Acid inhibits the reaction [SRR protein results in increased abundance of D-Aspartic Acid]]; Adenosine Triphosphate promotes the reaction [SRR protein results in increased abundance of D-Aspartic Acid]
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]]
Adenosine Triphosphate results in increased secretion of TAC1 protein Iloprost promotes the reaction [Adenosine Triphosphate results in increased secretion of TAC1 protein]
Adenosine Triphosphate results in decreased secretion of TIMP1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in decreased secretion of TIMP1 protein]
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]
[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Chlorides]; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Potassium]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased secretion of TNF protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA] TNF protein promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] TNF protein results in decreased chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein; [Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Rosiglitazone inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Vitamin K 3 promotes the reaction [[Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate]
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; copper-thiosemicarbazone complex analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]]; Emodin inhibits the reaction [TOP2A results in increased hydrolysis of Adenosine Triphosphate]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Thiosemicarbazones analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate] TOP2A protein results in increased hydrolysis of Adenosine Triphosphate; TOP2A results in increased hydrolysis of Adenosine Triphosphate
TOP2B protein results in increased hydrolysis of Adenosine Triphosphate cannabidiol hydroxyquinone inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]; Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]
TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] TP53 gene mutant form results in increased abundance of Adenosine Triphosphate
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]
ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Adenosine Triphosphate results in increased activity of TRPC3 protein]
Adenosine Triphosphate inhibits the reaction [UCP1 protein results in increased transport of Protons] UCP1 results in decreased abundance of Adenosine Triphosphate UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]
Adenosine Triphosphate inhibits the reaction [UCP2 protein results in increased transport of Protons] [SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]
Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in decreased abundance of Adenosine Triphosphate]; Acetylcysteine promotes the reaction [XRCC1 protein results in increased abundance of Adenosine Triphosphate]
[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]
Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein] Bucladesine results in increased activity of ABCC2 protein Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein]
Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form Bucladesine results in increased expression of ACHE mRNA
AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]]
Bucladesine affects the localization of AHR protein Bucladesine results in increased activity of AHR protein Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]
27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; T0901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form] Bucladesine results in increased phosphorylation of ATF2 protein
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]
adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] Bucladesine results in decreased expression of BCL2 protein
1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein]
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein
Bucladesine results in increased expression of CCND1 protein [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein
Bucladesine results in increased expression of CDKN1A protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]
Bucladesine results in increased expression of CEBPB protein Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein]
[Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein Bucladesine results in increased expression of CHAT protein Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein]
Bucladesine results in increased phosphorylation of CREB1 protein [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]] [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein]
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]] [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]
Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein] Bucladesine affects the localization of CTBP1 protein
Bucladesine results in increased expression of CYP11A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA] [Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA]
Bucladesine results in increased expression of CYP11B1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP11B1 mRNA]
Bucladesine results in decreased expression of CYP17A1 mRNA Bucladesine results in increased expression of CYP17A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP17A1 mRNA] [Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA]
Bucladesine results in increased expression of CYP19A1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of CYP19A1 mRNA]
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein]
[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA
Bucladesine results in increased expression of ESR1 mRNA [Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA]
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]]
Bucladesine results in increased expression of FAS mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA]
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA
FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]
[bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA]
Bucladesine affects the expression of FOS protein Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein] Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of and results in increased localization of FOXO1 protein]
IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC1 protein]] Bucladesine results in increased expression of G6PC1 mRNA; Bucladesine results in increased expression of G6PC1 protein
Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein]
[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the phosphorylation of CREB1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]]
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein]
[tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HMGCR mRNA]
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA]
Bucladesine results in decreased expression of HSD17B1 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in decreased expression of HSD17B1 mRNA]
Bucladesine results in increased expression of HSD3B2 mRNA fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of HSD3B2 mRNA]
Bucladesine results in increased expression of ID1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA]
Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]
Bucladesine results in increased expression of IGFBP1 [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]
Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]]
Bucladesine results in increased expression of IL23A mRNA [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein]
Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein]
[Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
Bucladesine results in decreased expression of INHA mRNA [Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA]
[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA]
Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein] [Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA]
Bucladesine results in decreased expression of LHCGR mRNA [Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA]
Bucladesine affects the localization of LIPE protein Bucladesine results in increased activity of LIPE protein Bucladesine results in increased expression of LIPE mRNA [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein Bucladesine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]]
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein Bucladesine results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA
bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein] Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein
[NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC1 mRNA]
[Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA
Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]
NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]
NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]
NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein] [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]; [Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 mRNA]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the expression of NR4A1 protein]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the methylation of NR4A1 promoter]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREB1 protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [CREBBP protein binds to NR4A1 promoter]]; methylmercuric chloride affects the reaction [[Doxycycline co-treated with Bucladesine co-treated with GDNF protein] affects the reaction [EZH2 protein binds to NR4A1 promoter]]
Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of NR5A1 protein] Bucladesine results in increased expression of NR5A1 mRNA; Bucladesine results in increased expression of NR5A1 protein NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]
bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein] Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein
Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA] Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]
Bucladesine results in increased expression of PF4 mRNA [Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA
Bucladesine results in increased expression of PLIN1 mRNA LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]
Bucladesine results in increased expression of PNPLA6 mRNA Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]
Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein]
Bucladesine results in increased expression of PPARG protein [ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein
Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA]
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein; [Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein; AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]; Losartan inhibits the reaction [AGT protein promotes the reaction [[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased secretion of PRL protein]]
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
Bucladesine results in decreased activity of RB1 protein Bucladesine results in decreased phosphorylation of RB1 protein Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein
Bucladesine results in increased expression of SLC18A3 protein Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein]
Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA]
Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein]
bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein] Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [T0901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] [IMOL S-140 co-treated with triphenyl phosphate co-treated with tris(chloroethyl)phosphate co-treated with diphenylcresyl phosphate co-treated with tert-butylphenyl diphenyl phosphate co-treated with tri-xylenyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; [tris(2-butoxyethyl) phosphate co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1,3-dichloro-2-propyl)phosphate co-treated with santicizer 148 co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; fluorene-9-bisphenol inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Organophosphates inhibits the reaction [Bucladesine results in increased expression of STAR mRNA] Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein Bucladesine results in decreased expression of STAR mRNA [Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA]
Bucladesine results in decreased expression of TESTIN mRNA Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]
Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]
[O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein; [phenylsaligenin cyclic phosphate co-treated with Bucladesine] results in increased activity of TGM2 protein
Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Bucladesine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] Bucladesine inhibits the reaction [Zymosan results in increased expression of TNF protein]
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of TP53 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of TP53 protein
Bucladesine results in increased expression of UCP1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of UCP1 mRNA]
[Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein
cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein]
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]]
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein cangrelor results in decreased activity of P2RY12 protein P2RY12 gene polymorphism affects the susceptibility to cangrelor
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]
NCEH1 protein inhibits the reaction [[Chlorpyrifos metabolite co-treated with Cytidine Diphosphate Choline] results in increased abundance of Platelet Activating Factor]
Cytidine Diphosphate Choline results in increased expression of SIRT1 protein Cytidine Diphosphate Choline results in increased expression of and results in increased activity of SIRT1 protein
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]]
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]]
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate
2'-deoxycytidine 5'-triphosphate promotes the reaction [N(2)-furfuryl-deoxyguanosine results in increased stability of POLK protein]; N-(2'-deoxyguanosin-8-yl)-3-aminobenzanthrone inhibits the reaction [POLK protein binds to 2'-deoxycytidine 5'-triphosphate]
Guanosine Diphosphate inhibits the reaction [Mersalyl results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [p-Chloromercuribenzoic Acid results in decreased activity of FUT8 protein]; Guanosine Diphosphate inhibits the reaction [Phenylglyoxal results in decreased activity of FUT8 protein] Guanosine Diphosphate results in decreased activity of FUT8 protein
[Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] promotes the reaction [HRAS protein binds to Guanosine Diphosphate]; Enzyme Inhibitors inhibits the reaction [SOS1 protein binds to [HRAS protein binds to Guanosine Diphosphate]]
Guanosine Diphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]
KRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]]; SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein] Guanosine Diphosphate binds to KRAS protein; Guanosine Diphosphate binds to KRAS protein mutant form
Guanosine Diphosphate binds to RAB3A protein [alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; [black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]
[Enzyme Inhibitors binds to and results in decreased activity of SOS1 protein] promotes the reaction [HRAS protein binds to Guanosine Diphosphate]; Enzyme Inhibitors inhibits the reaction [SOS1 protein binds to [HRAS protein binds to Guanosine Diphosphate]]; KRAS protein mutant form inhibits the reaction [SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]]; SOS1 protein inhibits the reaction [Guanosine Diphosphate binds to KRAS protein]
Resveratrol promotes the reaction [CDC42 protein binds to Guanosine Triphosphate]; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein]; Zoledronic Acid results in increased expression of [CDC42 protein binds to Guanosine Triphosphate] Ethanol results in decreased expression of [CDC42 protein binds to Guanosine Triphosphate] Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to CDC42 protein]
CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Risedronic Acid promotes the reaction [CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]]
[dicyanocobinamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]] which results in increased metabolism of Guanosine Triphosphate
[dicyanocobinamide results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]] which results in increased metabolism of Guanosine Triphosphate
Guanosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]
6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-pyridazin-3-one inhibits the reaction [alpha-methylhistamine promotes the reaction [Guanosine Triphosphate binds to HRH3 protein]]; alpha-methylhistamine promotes the reaction [Guanosine Triphosphate binds to HRH3 protein]
Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]; Guanosine Triphosphate affects the reaction [Serotonin inhibits the reaction [N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide binds to HTR1A protein]]; Manganese inhibits the reaction [Guanosine Triphosphate affects the reaction [Serotonin binds to HTR1A protein]]
Guanosine Triphosphate binds to KRAS protein; Guanosine Triphosphate binds to KRAS protein mutant form KRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]]; RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate] KRAS protein mutant form results in increased hydrolysis of Guanosine Triphosphate; KRAS protein results in increased hydrolysis of Guanosine Triphosphate
Guanosine Triphosphate inhibits the reaction [Carbaryl inhibits the reaction [Melatonin binds to MTNR1B protein]]; Guanosine Triphosphate inhibits the reaction [Carbofuran inhibits the reaction [Melatonin binds to MTNR1B protein]]
[Guanosine Triphosphate co-treated with Lithium] results in decreased activity of POMC protein modified form; [Guanosine Triphosphate co-treated with Potassium] results in decreased activity of POMC protein modified form; [Guanosine Triphosphate co-treated with Sodium Chloride] results in decreased activity of POMC protein modified form
[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein; Guanosine Triphosphate binds to RAB3A protein; RAB3A protein binds to Guanosine Triphosphate; SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate] RAB3A protein results in increased cleavage of Guanosine Triphosphate [alpha-latrotoxin promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; [black widow spider venom promotes the reaction [RAB3A protein results in increased cleavage of Guanosine Triphosphate]] promotes the reaction [Guanosine Diphosphate binds to RAB3A protein]; manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]; manganese chloride promotes the reaction [SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate]]; manganese chloride results in increased expression of [RAB3A protein binds to Guanosine Triphosphate]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]]
manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]]
Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Zoledronic Acid results in increased expression of [RAC1 protein binds to Guanosine Triphosphate] Ethanol results in decreased expression of [RAC1 protein binds to Guanosine Triphosphate] CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; GGTI 298 results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; mevastatin results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Risedronic Acid promotes the reaction [CSF1 protein results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]]; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to RAC1 protein]
KRAS protein mutant form inhibits the reaction [RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]]; RASA1 protein promotes the reaction [KRAS protein results in increased hydrolysis of Guanosine Triphosphate]
Dronabinol inhibits the reaction [Guanosine Triphosphate binds to and results in increased activity of RHOA protein]; Guanosine Triphosphate binds to and results in increased activity of RHOA protein; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein]; Zoledronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein] 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one promotes the reaction [Guanosine Triphosphate binds to RHOA protein] Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]; Cadmium Chloride promotes the reaction [RHOA protein binds to Guanosine Triphosphate]; Dronabinol inhibits the reaction [Guanosine Triphosphate binds to and results in increased activity of RHOA protein]; Guanosine Triphosphate binds to and results in increased activity of RHOA protein; Risedronic Acid results in increased abundance of [Guanosine Triphosphate binds to RHOA protein]; tempol inhibits the reaction [Asbestos, Crocidolite inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; tempol inhibits the reaction [Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]]; Vitamin K 3 inhibits the reaction [RHOA protein binds to Guanosine Triphosphate]; Zoledronic Acid results in increased expression of [RHOA protein binds to Guanosine Triphosphate]
manganese chloride promotes the reaction [SNCA protein binds to [RAB3A protein binds to Guanosine Triphosphate]]; SNCA protein promotes the reaction [manganese chloride inhibits the reaction [[RAB3A protein binds to Guanosine Triphosphate] which binds to RABGAP1 protein]]
ADORA2A protein affects the reaction [[Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate)]
(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone metabolite promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; 5F-CUMYL-PICA promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; AM 6527 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; Dronabinol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR1 protein]; XLR-11 metabolite promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; XLR-11 promotes the reaction [CNR1 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]
(1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone metabolite promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; 4-hydroxy-N-desmethyltamoxifen inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; 5F-CUMYL-PICA promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; afimoxifene inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; AM 281 inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; AM 6527 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; cannabinoid CB2 receptor agonist ABK5 promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; Dronabinol promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; iodopravadoline inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; ridaifen-B inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; Tamoxifen inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to CNR2 protein]; XLR-11 metabolite promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]; XLR-11 promotes the reaction [CNR2 protein binds to Guanosine 5'-O-(3-Thiotriphosphate)]
Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of GPR55 protein] affects the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein]
[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of GPR55 protein] affects the reaction [Guanosine 5'-O-(3-Thiotriphosphate) binds to GNA13 protein]
[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased phosphorylation of MYL9 protein]
[7-benzylidenenaltrexone binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate); [chlornaltrexamine binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate); [clocinnamox binds to and results in decreased activity of OPRM1 protein] which affects the localization of Guanosine 5'-O-(3-Thiotriphosphate) [Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate); ADORA2A protein affects the reaction [[Enkephalin, Ala(2)-MePhe(4)-Gly(5)- binds to OPRM1 protein] which results in increased activity of Guanosine 5'-O-(3-Thiotriphosphate)]
[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein; Caffeine inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Caffeine inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [[3,4-dihydroxyphenylglycol co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCB1 protein]; Theophylline inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of PLCB1 protein]
[[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]; [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein; PLCG2 protein mutant form results in decreased susceptibility to [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)]
Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein dioleoylphosphatidic acid analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]; Oleic Acid promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]; phosphatidylethanol analog promotes the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PLEK protein]
Guanosine 5'-O-(3-Thiotriphosphate) inhibits the reaction [15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid results in increased phosphorylation of PPP1R12A protein] Guanosine 5'-O-(3-Thiotriphosphate) results in increased phosphorylation of PPP1R12A protein
Methohexital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Pentobarbital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Secobarbital inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]; Thiamylal inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) results in increased activity of RAC1 protein]
[[RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein] which results in increased chemical synthesis of Inositol Phosphates; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]; [Guanosine 5'-O-(3-Thiotriphosphate) co-treated with RAC2 protein] promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates]; [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)] results in increased activity of PLCG2 protein; PLCG2 protein mutant form results in decreased susceptibility to [RAC2 protein co-treated with Guanosine 5'-O-(3-Thiotriphosphate)]
Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of RHOA protein [Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Guanosine 5'-O-(3-Thiotriphosphate)] which results in increased localization of RHOA protein]; Sevoflurane inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of RHOA protein]
Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of ROCK2 protein sevoflurane inhibits the reaction [Guanosine 5'-O-(3-Thiotriphosphate) affects the localization of ROCK2 protein]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate] APP protein mutant form results in increased abundance of Inosine Monophosphate PF-06840003 inhibits the reaction [APP protein mutant form results in increased abundance of Inosine Monophosphate]
[Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]]
[potassium oxonate co-treated with Inosine Monophosphate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]]
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of Inosine Monophosphate]
[Inosine Monophosphate co-treated with potassium oxonate] inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; SCH 442416 inhibits the reaction [Inosine Monophosphate inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]]
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of AR mRNA]
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased activity of HIF1A protein]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of IRS2 mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA]; CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of VEGFA protein] monobutyryl cyclic AMP results in increased expression of CREM mRNA CREM protein results in decreased susceptibility to monobutyryl cyclic AMP
EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased activity of HIF1A protein]; monobutyryl cyclic AMP results in increased expression of and affects the localization of and results in increased activity of HIF1A protein
monobutyryl cyclic AMP results in increased expression of IRS2 mRNA CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of IRS2 mRNA]
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK1 protein]
[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein; azalanstat inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; EGF protein inhibits the reaction [naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]]; naphthol AS-E phosphate inhibits the reaction [[monobutyryl cyclic AMP co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of NR4A2 mRNA]
monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of PPARGC1A mRNA]
monobutyryl cyclic AMP results in increased expression of VEGFA protein CREM protein inhibits the reaction [monobutyryl cyclic AMP results in increased expression of VEGFA protein]
NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]
[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]
[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]
[ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein] NAD results in increased activity of ALDH1A1 protein
[ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde
[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein] ALDH2 protein binds to NAD NAD binds to ALDH2 protein Magnesium affects the reaction [NAD binds to ALDH2 protein] ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD
[ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde NAD results in increased activity of ALDH3A1 protein
NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CYB5R3 protein binds to NAD [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]
[epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein] nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] NAD results in increased ADP-ribosylation of ERCC6 protein ERCC6 gene mutant form results in increased metabolism of NAD
[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
GSK3B protein mutant form results in increased abundance of NAD metabolite 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]
[Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]
[Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein
[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein
IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]
NAD results in increased expression of IGFBP1 mRNA NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA]
2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]
MIR34A mRNA results in decreased abundance of NAD [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine]
[MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
[NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD
NAMPT protein results in increased chemical synthesis of NAD [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]
P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD] 5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD] PARP1 protein mutant form affects the abundance of NAD [2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] PARP1 protein affects the abundance of NAD
PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein] SIRT1 protein results in increased susceptibility to NAD NAD results in increased activity of SIRT1 protein [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein] NAD results in decreased expression of TP53 protein
ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]
[thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein
XRCC1 gene mutant form results in decreased reduction of NAD [XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
NAD promotes the reaction [AKR1A1 protein affects the chemical synthesis of benzo(a)pyrene-7,8-dione]; NAD promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]
[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C2 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]
[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol; dichloro(4-cymene)ruthenium(II) analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; dichloro(4-cymene)ruthenium(II) inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]; Ruthenium Compounds analog inhibits the reaction [[AKR1C3 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of AKT1 protein]
[ALDH1A1 protein binds to NAD] which results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of propionaldehyde; [ALDH1A1 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; [NAD co-treated with propionaldehyde] inhibits the reaction [Acrolein results in decreased activity of ALDH1A1 protein]; ALDH1A1 protein binds to and results in increased reduction of NAD; NAD binds to and results in increased activity of ALDH1A1 protein; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH1A1 protein] NAD results in increased activity of ALDH1A1 protein
[ALDH1B1 protein co-treated with NAD] results in increased metabolism of Acetaldehyde; [ALDH1B1 protein co-treated with NAD] results in increased metabolism of propionaldehyde
[ALDH2 protein co-treated with NAD] results in increased oxidation of Retinaldehyde; NAD inhibits the reaction [[Ethanol co-treated with Lead] results in decreased expression of and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Acrolein binds to and results in decreased activity of ALDH2 protein]; NAD inhibits the reaction [Ethanol results in decreased expression of and results in decreased activity of ALDH2 protein] ALDH2 protein binds to NAD NAD binds to ALDH2 protein Magnesium affects the reaction [NAD binds to ALDH2 protein] ALDH2 gene polymorphism affects the abundance of NAD; ALDH2 protein affects the abundance of NAD
[ALDH3A1 protein co-treated with NAD] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NAD] results in increased oxidation of benzaldehyde NAD results in increased activity of ALDH3A1 protein
NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; NAD inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; NAD inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]
CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]
NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]
NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]
CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
CYB5R3 protein binds to NAD [MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; [MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased reduction of Diacetyl; [DCXR protein co-treated with NAD] results in increased reduction of Xylulose; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]
[epigallocatechin gallate results in decreased activity of ENOX2 protein] which results in increased abundance of NAD; [phenoxodiol results in decreased activity of ENOX2 protein] which results in increased abundance of NAD
ERCC6 gene mutant form promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased abundance of NAD]; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein] nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of NAD] NAD results in increased ADP-ribosylation of ERCC6 protein ERCC6 gene mutant form results in increased metabolism of NAD
[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog; Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NAD analog inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]; NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with 3-phosphoglycerate co-treated with NAD] results in increased reduction of sodium arsenate analog]; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
GSK3B protein mutant form results in increased abundance of NAD metabolite 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of GSK3B protein]
[Celecoxib co-treated with NAD] binds to HPGD protein; [Diclofenac co-treated with NAD] binds to HPGD protein; [Dinoprostone co-treated with NAD] binds to HPGD protein; [Fenoprofen co-treated with NAD] binds to HPGD protein; [Indomethacin co-treated with NAD] binds to HPGD protein; [Ketoprofen co-treated with NAD] binds to HPGD protein; [Niflumic Acid co-treated with NAD] binds to HPGD protein; [pioglitazone co-treated with NAD] binds to HPGD protein; [rosiglitazone co-treated with NAD] binds to HPGD protein; NAD binds to and results in increased activity of HPGD protein
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of HRAS gene]
[Androstane-3,17-diol co-treated with NAD] binds to HSD11B1 protein; [Disulfiram co-treated with NAD] binds to HSD11B1 protein; [Estradiol co-treated with NAD] binds to HSD11B1 protein; [Quercetin co-treated with NAD] binds to HSD11B1 protein; [Testosterone co-treated with NAD] binds to HSD11B1 protein
[20-hydroxycholesterol co-treated with NAD] binds to HSD17B10 protein; [Androstane-3,17-diol co-treated with NAD] binds to HSD17B10 protein; [cholest-5-en-3 beta,7 alpha-diol co-treated with NAD] binds to HSD17B10 protein; [Cholestanol co-treated with NAD] binds to HSD17B10 protein; [Pregnanolone co-treated with NAD] binds to HSD17B10 protein; [Progesterone co-treated with NAD] binds to HSD17B10 protein; NAD binds to and results in increased activity of HSD17B10 protein
IDH2 protein mutant form results in increased abundance of NAD; IDH2 protein mutant form results in increased abundance of NAD metabolite Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD metabolite]; Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NAD]
NAD inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Cyclic AMP] results in increased expression of IGFBP1 mRNA] NAD results in increased expression of IGFBP1 mRNA
2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; [NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Bungarotoxins inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; CHRNA9 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [[NAD results in increased secretion of Biological Factors] inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; conotoxin alpha-RgIA, Conus regius analog inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]; P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; P2RY11 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]; Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]]; [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride co-treated with NAD] inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]; NAD inhibits the reaction [Oleic Acid results in decreased phosphorylation of INSR protein]
[[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]
[MTARC1 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine; NAD affects the reaction [MTARC1 protein results in increased reduction of trimethyloxamine]
[MTARC2 protein co-treated with CYB5B protein co-treated with CYB5R3 protein co-treated with NAD] results in increased reduction of sulfamethoxazole hydroxylamine
[NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD
NAMPT protein results in increased chemical synthesis of NAD [[MIR34A mRNA binds to NAMPT 3' UTR] which results in decreased expression of NAMPT mRNA] which results in decreased abundance of NAD; [Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD; [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased activity of NAMPT protein] which results in decreased abundance of NAD; MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]; NAMPT protein affects the reaction [MIR34A mRNA results in decreased abundance of NAD]; Niacinamide inhibits the reaction [[Acetaminophen results in decreased expression of NAMPT protein] which results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Resveratrol inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]
P2RY1 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD; benzamide inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; benzamide inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Hydrogen Peroxide results in increased activity of PARP1 protein] which results in decreased abundance of NAD]; Hydrolyzable Tannins inhibits the reaction [[Methylnitronitrosoguanidine results in increased activity of PARP1 protein] which results in decreased abundance of NAD] PARP1 protein results in decreased abundance of NAD 5-chloro-2-(3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl)-4(3H)-quinazolinone inhibits the reaction [PARP1 protein results in decreased abundance of NAD] PARP1 protein mutant form affects the abundance of NAD [2,5,2',5'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3,4,3',4'-tetrachlorobiphenyl results in increased activity of PARP1 protein] which results in decreased abundance of NAD; [3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NAD]; [NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein; [PARP1 protein co-treated with NAD] results in increased ADP-ribosylation of NR1H3 protein; ERCC6 inhibits the reaction [NAD results in increased activity of PARP1 protein]; Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[NAD co-treated with Oleic Acid] results in increased activity of PARP1 protein]; PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; PARP1 protein promotes the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; veliparib inhibits the reaction [Hydrogen Peroxide affects the reaction [PARP1 protein mutant form affects the abundance of NAD]]; veliparib inhibits the reaction [PARP1 protein mutant form affects the abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]] PARP1 protein affects the abundance of NAD
PLA2G6 protein promotes the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein]]; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; [Resveratrol results in increased abundance of NAD] which results in increased expression of SIRT1 protein; NAD promotes the reaction [Oleic Acid results in decreased activity of SIRT1 protein] SIRT1 protein results in increased susceptibility to NAD NAD results in increased activity of SIRT1 protein [MIR34A mRNA results in decreased abundance of NAD] which results in decreased activity of SIRT1 protein NAD inhibits the reaction [Glucose results in decreased expression of SIRT1 protein]; Niacinamide inhibits the reaction [SIRT1 protein results in decreased abundance of NAD]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1A protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of CDKN1B protein]]; SIRT1 protein promotes the reaction [NAD inhibits the reaction [Glucose results in increased expression of GLB1 protein]]
[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene; [[Resveratrol results in increased activity of and results in increased phosphorylation of SIRT1 protein] which co-treated with NAD] results in decreased acetylation of TP53 protein; bathocuproine inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene]; CAT protein inhibits the reaction [[2-phenylphenol metabolite co-treated with NAD co-treated with Copper] results in increased mutagenesis of TP53 gene] NAD promotes the reaction [Acetaminophen results in decreased expression of TRP53 protein] NAD results in decreased expression of TP53 protein
ethylenediamine inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]; Glutathione inhibits the reaction [[TYR protein results in increased oxidation of caffeic acid phenethyl ester] which results in increased oxidation of NAD]
[thymidine 5'-diphosphate co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Galactose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucose co-treated with NAD] binds to UXS1 protein; [Uridine Diphosphate Glucuronic Acid co-treated with NAD] binds to UXS1 protein
XRCC1 gene mutant form results in decreased reduction of NAD [XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD; olaparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; veliparib affects the reaction [[XRCC1 protein affects the susceptibility to Camptothecin] which affects the abundance of NAD]; XRCC1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]; XRCC1 protein affects the reaction [PARP1 protein affects the reaction [Hydrogen Peroxide results in decreased abundance of NAD]]
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]
Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Losartan inhibits the reaction [AGT protein results in decreased abundance of NADP]
[AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione NADP results in increased activity of AKR1B1 protein NADP binds to AKR1B1 protein binds to fidarestat
[AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione NADP results in increased activity of AKR1B10 protein NADP binds to AKR1B10 protein mutant form binds to fidarestat AKR1B10 protein results in decreased reduction of NADP
[AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone]
[AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone]
[AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone]
[AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone
[[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes
[AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]
[ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde NADP results in increased activity of ALDH3A1 protein
[diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein]
[CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein
CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide] [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein
[CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog
[CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein]
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein]
[CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine] [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein
NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein]
[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]
[NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein
CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]
NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]]
NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein] GSR protein results in increased oxidation of NADP caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP] Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]
NADP binds to and results in increased activity of HSD11B1 protein HSD11B1 protein results in increased reduction of NADP Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]
[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein] NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein
[Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein
[22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein
IDH2 protein mutant form results in increased abundance of NADP Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
NADP binds to KCNAB2 protein [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
[Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
[3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]
[Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein
NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3] [POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP] [POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]
[NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein] [Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]
[PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
TALDO1 gene mutant form results in decreased abundance of NADP Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]
NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein] NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]] TIGAR protein results in increased abundance of NADP
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein] NADP results in increased reduction of TXNRD1 protein [Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [arsenic trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; NADP promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]
Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Losartan inhibits the reaction [AGT protein results in decreased abundance of NADP]
[AKR1A1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1A1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1A1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[AKR1B1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1B1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione NADP results in increased activity of AKR1B1 protein NADP binds to AKR1B1 protein binds to fidarestat
[AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde; [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione NADP results in increased activity of AKR1B10 protein NADP binds to AKR1B10 protein mutant form binds to fidarestat AKR1B10 protein results in decreased reduction of NADP
[AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone]
[AKR1C2 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone; NADP inhibits the reaction [AKR1C2 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C2 protein results in increased reduction of cyclopentanone]; Ursodeoxycholic Acid inhibits the reaction [[AKR1C2 protein co-treated with NADP] results in increased reduction of cyclopentanone]
[AKR1C3 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7,8-dihydrodiol; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR1C3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein co-treated with NADP] results in increased reduction of cyclopentanone]; NADP inhibits the reaction [AKR1C3 protein results in increased oxidation of Hydroxysteroids]; NADP promotes the reaction [AKR1C3 protein results in increased reduction of cyclopentanone]
[AKR1D1 protein co-treated with NADP] results in increased reduction of 7 alpha-hydroxy-4-cholesten-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of cholest-4-en-3-one; [AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone; [AKR1D1 protein co-treated with NADP] results in increased reduction of Testosterone
[[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone] which results in increased chemical synthesis of Superoxides; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in decreased abundance of Oxygen; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Hydrogen Peroxide; [[AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione] which results in increased chemical synthesis of Superoxides; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [AKR7A2 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes
[AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione
1-benzylimidazole inhibits the reaction [NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]]; NADP promotes the reaction [Thiocarbamates analog results in decreased activity of ALDH2 protein]
[ALDH3A1 protein co-treated with NADP] results in increased oxidation of aldophosphamide; [ALDH3A1 protein co-treated with NADP] results in increased oxidation of benzaldehyde NADP results in increased activity of ALDH3A1 protein
[diphenylcresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tert-butylphenyl diphenyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; [tri-o-cresyl phosphate co-treated with NADP] results in decreased activity of BCHE protein; naringenin inhibits the reaction [[Tritolyl Phosphates co-treated with NADP] results in decreased activity of BCHE protein]
[CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [CBR1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [Genistein co-treated with NADP] binds to CBR1 protein; [Quercetin co-treated with NADP] binds to CBR1 protein; [Triclosan co-treated with NADP] binds to CBR1 protein; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein]; NADP binds to and results in increased activity of CBR1 protein; NADP metabolite binds to and results in increased activity of CBR1 protein
CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]
NADP promotes the reaction [CYP1A1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide] [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP1A1 protein
[CYP1A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with binimetinib] results in decreased activity of CYP1A2 protein; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [Cimetidine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Enoxacin inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine]]; NADP promotes the reaction [Resveratrol results in decreased activity of CYP1A2 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,2',4,6'-tetramethoxystilbene; [CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene; alpha-naphthoflavone inhibits the reaction [[CYP1B1 protein co-treated with NADP] results in increased metabolism of 2,4,3',5'-tetramethoxystilbene]; NADP promotes the reaction [CYP1B1 protein affects the chemical synthesis of 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide]; NADP promotes the reaction [CYP1B1 protein affects the metabolism of and results in increased activity of benzo(a)pyrene 7,8-dihydrodiol]
[NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene; [NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog; [NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog
[CYP2A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; [CYP2B6 protein co-treated with cupric chloride co-treated with NADP] results in increased metabolism of N'-nitrosonornicotine; [Ethinyl Estradiol co-treated with NADP] results in decreased activity of CYP2B6 protein; [isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein; Mephenytoin inhibits the reaction [[isoimperatorin co-treated with NADP] results in decreased activity of CYP2B6 protein]
[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein; [CYP2C19 protein co-treated with NADP] results in increased metabolism of Oxymetazoline; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; CYP2C19 protein results in increased metabolism of [alpha-Linolenic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Docosahexaenoic Acids co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Eicosapentaenoic Acid co-treated with NADP]; CYP2C19 protein results in increased metabolism of [Linoleic Acid co-treated with NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ticlopidine inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP2C19 protein]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein; CAT protein inhibits the reaction [[2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2D2 protein]
[CYP2D6 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP deficiency inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[vinyl carbamate co-treated with NADP] inhibits the reaction [CYP2E1 protein results in decreased methylation of Dimethylnitrosamine] [2-dichlorobenzene analog co-treated with NADP] results in decreased activity of CYP2E1 protein
NADP promotes the reaction [azelnidipine results in decreased activity of CYP2J2 protein]; NADP promotes the reaction [Felodipine results in decreased activity of CYP2J2 protein]
[CYP3A2 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine [2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine; [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine; [CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [NADP co-treated with CYP3A4 protein] results in increased activity of imidacloprid analog; [NADP co-treated with CYP3A4 protein] results in increased activity of Thiamethoxam; [retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; Dextromethorphan inhibits the reaction [[retrorsine co-treated with NADP] results in decreased activity of CYP3A4 protein]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Ketoconazole inhibits the reaction [[2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucopyranoside co-treated with NADP] results in decreased activity of CYP3A4 protein]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Midazolam] which results in increased chemical synthesis of 1-hydroxymethylmidazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 12-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 13-hydroxyellipticine]; Protons inhibits the reaction [[[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine] which results in increased chemical synthesis of 9-hydroxyellipticine]; Protons inhibits the reaction [[CYP3A4 protein co-treated with NADP] results in increased oxidation of ellipticine]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[CYP3A23-3A1 protein co-treated with NADP co-treated with Glutathione] results in increased glutathionylation of and results in increased activity of 7-methoxy-N-((6-(3-methylisothiazol-5-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-yl)methyl)-1,5-naphthyridin-4-amine
[2,6-dimethyl-1,4-benzoquinone co-treated with NADP] binds to DCXR protein; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [CBR2 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes; [DCXR protein co-treated with NADP] results in increased reduction of Diacetyl; [DCXR protein co-treated with NADP] results in increased reduction of Xylulose; [Disulfiram co-treated with NADP] binds to DCXR protein; [Vitamin K 3 co-treated with NADP] binds to DCXR protein; Butyric Acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; Heptanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; hexanoic acid inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]; NADP binds to and results in increased activity of DCXR protein; Pentanoic Acids inhibits the reaction [[DCXR protein co-treated with NADP] results in increased reduction of Diacetyl]
[NADP co-treated with DHRS2 protein] affects the metabolism of 1-phenyl-1,2-propanedione; [NADP co-treated with DHRS2 protein] affects the metabolism of diethylglyoxime; [NADP co-treated with DHRS2 protein] affects the metabolism of Ketones; NADP binds to and results in increased activity of DHRS2 protein
CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]
[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-aminophenol; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoro-N-methylaniline metabolite; [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of 4-fluoroaniline; [[FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased oxidation of 4-fluoro-N-methylaniline [[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol; [FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline; Methimazole inhibits the reaction [[[FMO1 protein co-treated with NADP] results in increased metabolism of 4-fluoro-N-methylaniline] which results in increased chemical synthesis of N-methyl-4-aminophenol]
NADP inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog]
[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]; dipicolinic acid inhibits the reaction [[GLUD1 protein co-treated with Ketoglutaric Acids co-treated with NADP co-treated with Aminooxyacetic Acid] affects the reaction [Carbon Tetrachloride affects the abundance of Ammonia]]
NADP affects the reaction [benzyl isothiocyanate results in decreased activity of GSR protein]; NADP affects the reaction [Carmustine results in decreased activity of GSR protein] GSR protein results in increased oxidation of NADP caffeic acid inhibits the reaction [Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP]]; Tetradecanoylphorbol Acetate inhibits the reaction [GSR protein results in increased oxidation of NADP] Acetylcysteine inhibits the reaction [arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]]; arsenic trioxide inhibits the reaction [GSR protein results in increased oxidation of NADP]; Potassium Dichromate promotes the reaction [GSR protein results in increased oxidation of NADP]
NADP binds to and results in increased activity of HSD11B1 protein HSD11B1 protein results in increased reduction of NADP Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]
[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone; coumarin analog inhibits the reaction [[HSD17B1 protein co-treated with NADP] results in increased reduction of Estrone]; NADP binds to and results in increased activity of HSD17B1 protein
NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein] NADP analog inhibits the reaction [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of HSD17B3 protein]; NADP binds to and results in increased activity of HSD17B3 protein
[Carbenoxolone co-treated with NADP] binds to HSD3B1 protein; [Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein; [Vitamin K 3 co-treated with NADP] binds to HSD3B1 protein
[22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein; [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; [Estradiol co-treated with NADP] binds to HSDL2 protein; [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein; NADP binds to and results in increased activity of HSDL2 protein
IDH2 protein mutant form results in increased abundance of NADP Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of NADP]
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
NADP binds to KCNAB2 protein [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxycyclopentenone)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-(epoxyisoprostane-E2)-sn-glycero-3-phosphocholine; [KCNAB2 protein co-treated with NADP] results in increased reduction of 1-palmitoyl-2-arachidonyl-3-phosphorylcholine metabolite
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]
[Niflumic Acid co-treated with NADP] binds to NMRAL1 protein; [Triclosan co-treated with NADP] binds to NMRAL1 protein; NADP binds to and results in increased activity of NMRAL1 protein
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of 9,10-phenanthrenequinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-1,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-3,6-quinone; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7,8-dione; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Chrysenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Dihydroxydihydrobenzopyrenes; [NQO1 protein co-treated with NADP] results in increased reduction of and affects the activity of Naphthalenes NADP promotes the reaction [NQO1 protein results in increased reduction of Vitamin K 3]
[3-aminobenzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [benzamide results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]; [coumarin results in decreased activity of PARP1 protein] inhibits the reaction [Tetrachlorodibenzodioxin results in decreased abundance of NADP]
[Acyl Coenzyme A co-treated with NADP] binds to PECR protein; [decanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein; [lauroyl-coenzyme A co-treated with NADP] binds to PECR protein; NADP binds to and results in increased activity of PECR protein
NADP affects the reaction [POR protein affects the metabolism of Nitrofurantoin]; NADP promotes the reaction [POR protein results in increased reduction of Vitamin K 3] [POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP] [POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP; [POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 7-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 9-hydroxyellipticine; [CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased oxidation of ellipticine; [NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid; [POR protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; [POR protein co-treated with NADP] results in increased chemical synthesis of Hydrogen Peroxide; CYB5A protein promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of NADP]; diphenyleneiodonium inhibits the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of NADP]; Ketoconazole affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; NADP promotes the reaction [[POR protein results in increased metabolism of Diquat] which results in increased metabolism of Oxygen]; NADP promotes the reaction [[POR protein results in increased metabolism of Paraquat] which results in increased metabolism of Oxygen]; Quercetin inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Thioctic Acid inhibits the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]; Tranylcypromine affects the reaction [[NADP co-treated with CYP1A2 protein co-treated with CYP2C8 protein co-treated with CYP2C9 protein co-treated with CYP2C19 protein co-treated with CYP2D6 protein co-treated with CYP3A4 protein co-treated with POR protein] results in increased metabolism of 1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid]
[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]
[NADP co-treated with cupric chloride] promotes the reaction [PRNP protein binds to PRNP protein] [Copper co-treated with NADP] promotes the reaction [PRNP protein binds to PRNP protein]; [Copper co-treated with NADP] results in increased susceptibility to [PRNP protein binds to PRNP protein]
[PTGR1 protein co-treated with NADP] affects the reduction of (2E)-decenal; [PTGR1 protein co-treated with NADP] affects the reduction of 1-pentene-3-one; [PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-butenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-octenal; [PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal; [PTGR1 protein co-treated with NADP] affects the reduction of 3-buten-2-one; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal; [PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-nonenal; [PTGR1 protein co-treated with NADP] affects the reduction of Acrolein; [PTGR1 protein co-treated with NADP] affects the reduction of benzylideneacetone; [PTGR1 protein co-treated with NADP] affects the reduction of Chalcone; [PTGR1 protein co-treated with NADP] affects the reduction of cinnamaldehyde; [PTGR1 protein co-treated with NADP] results in increased reduction of and results in increased activity of acylfulvene
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone
TALDO1 gene mutant form results in decreased abundance of NADP Acetylcysteine inhibits the reaction [TALDO1 gene mutant form results in decreased abundance of NADP]
NADP inhibits the reaction [Kainic Acid results in decreased expression of TIGAR protein] TIGAR protein results in increased abundance of NADP NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]
[TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
[NADP co-treated with Mechlorethamine] results in decreased activity of TXNRD1 protein; NADP affects the reaction [benzyl isothiocyanate results in decreased activity of TXNRD1 protein] NADP results in increased reduction of TXNRD1 protein [Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein; [NADP co-treated with Mechlorethamine] promotes the reaction [TXNRD1 protein binds to TXNRD1 protein]; [NADP co-treated with Mechlorethamine] results in decreased activity of and results in increased alkylation of TXNRD1 protein; [NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein; [Sodium Selenite co-treated with NADP] inhibits the reaction [Mercuric Chloride results in decreased activity of TXNRD1 protein]; [TXN1 protein co-treated with INS1 protein] inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; [TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides; Auranofin inhibits the reaction [[NADP co-treated with TXNRD1 protein] results in increased activity of PPIF protein]; Auranofin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dinitrochlorobenzene promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Dithionitrobenzoic Acid inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; formic acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Glutathione inhibits the reaction [[Mitomycin co-treated with NADP] results in decreased activity of TXNRD1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; NADP affects the reaction [Arsenic Trioxide results in decreased activity of TXNRD1 protein]; Oxygen deficiency inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Pentetic Acid promotes the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]; Sodium Selenite inhibits the reaction [[TXNRD1 protein co-treated with NADP] results in increased abundance of Superoxides]
CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]
CD38 gene mutant form inhibits the reaction [FASL protein results in increased abundance of NAADP]; CD38 gene mutant form inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]; CD38 gene mutant form promotes the reaction [Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]]; NADP promotes the reaction [FASL protein results in increased abundance of NAADP]; Niacinamide inhibits the reaction [NADP promotes the reaction [FASL protein results in increased abundance of NAADP]]
NAADP results in increased activity of MCOLN1 protein [NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium
Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in increased expression of AXIN1 protein]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased activity of BGLAP protein]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in decreased expression of BGLAP protein]
Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CCND1 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Dicumarol inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]]; Nicotinamide Mononucleotide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN2A protein]
Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein]; Nicotinamide Mononucleotide inhibits the reaction [N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide results in decreased expression of CTNNB1 protein]
Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL18 protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of IL1B protein]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA]
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased abundance of NAD]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of ACADM mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARA mRNA]; Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA]
NAMPT protein binds to Nicotinamide Mononucleotide Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CCND1 protein]; Nicotinamide Mononucleotide affects the reaction [NAMPT protein affects the expression of CTNNB1 protein] Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein] Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of NLRP3 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of FOXO4 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]
Nicotinamide Mononucleotide results in increased expression of NQO1 protein 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide results in increased expression of NQO1 protein]
PARP1 protein affects the abundance of Nicotinamide Mononucleotide [Nicotinamide Mononucleotide co-treated with Cisplatin] results in decreased expression of PARP1 protein; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PARP1 mRNA]
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA results in decreased expression of PPARD mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of PPARD mRNA]
Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of PPARGC1A mRNA]
Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in decreased expression of SHANK2 mRNA]
Nicotinamide Mononucleotide results in increased expression of SIRT1 mRNA Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of SIRT1 mRNA] Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in decreased expression of SIRT1 protein]
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]]; Nicotinamide Mononucleotide inhibits the reaction [[NNT protein inhibits the reaction [NNT protein modified form results in decreased susceptibility to Cisplatin]] which results in increased expression of SQSTM1 protein]
Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Nicotinamide Mononucleotide inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]
Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein] Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP mRNA]; Nicotinamide Mononucleotide inhibits the reaction [Aluminum Chloride results in increased expression of TXNIP protein]
Nicotinamide Mononucleotide inhibits the reaction [Ethanol results in increased expression of UCP2 protein] Nicotinamide Mononucleotide inhibits the reaction [Zearalenone results in increased expression of UCP2 mRNA]
[NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of adenosine 5'-tetraphosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; manganese chloride promotes the reaction [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate]
P(1),P(5)-di(adenosine-5'-)pentaphosphate analog inhibits the reaction [[Nitrites co-treated with Oxygen deficiency] results in increased expression of SIRT1 mRNA]
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate; [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate
ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A [ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]
Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
Poly G inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA]; Poly G inhibits the reaction [Particulate Matter results in increased expression of ACTA2 protein]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]
Poly G inhibits the reaction [Particulate Matter results in decreased expression of CDH1 mRNA]; Poly G inhibits the reaction [Particulate Matter results in decreased expression of CDH1 protein]; Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]
Poly G inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL1A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL1A1 protein]
Poly G inhibits the reaction [Particulate Matter results in increased expression of COL3A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]
Poly G inhibits the reaction [MARCO protein binds to and results in increased uptake of Polystyrenes] Poly G inhibits the reaction [Particulate Matter results in increased expression of MARCO protein]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of MARCO protein]
Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of PPARGC1A mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in decreased expression of PPARGC1A protein]
Poly G inhibits the reaction [Particulate Matter results in increased expression of VIM mRNA]; Poly G inhibits the reaction [Particulate Matter results in increased expression of VIM protein]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of VIM mRNA]; Poly G inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein]
Poly I-C results in increased expression of AHR mRNA; Poly I-C results in increased expression of AHR protein AHR protein affects the reaction [[Poly I-C co-treated with Tetrachlorodibenzodioxin] results in increased expression of IL22 mRNA]
Poly I-C results in increased degradation of APPL1 protein APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IKBKE protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; trametinib inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein]
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of BDNF mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of BDNF mRNA] Poly I-C affects the methylation of BDNF promoter
Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP3 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]
arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP8 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP8 protein]
Acetylcysteine inhibits the reaction [arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]]; Acetylcysteine inhibits the reaction [Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]]; arsenic trioxide promotes the reaction [Poly I-C results in increased activity of CASP9 protein]; Poly I-C promotes the reaction [arsenic trioxide results in increased activity of CASP9 protein]
methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL2 protein] Poly I-C results in increased expression of CCL2 mRNA
Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL3 protein] [TL8-506 co-treated with Poly I-C] results in increased expression of CCL3 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of CCL3 protein
Ethanol inhibits the reaction [Poly I-C results in increased expression of CCL4 protein]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL4 protein] 6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA]; [TL8-506 co-treated with Poly I-C] results in increased expression of CCL4 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of CCL4 protein; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of CCL4 mRNA]
APPL1 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CCL5 protein]; trametinib promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA] Poly I-C results in increased expression of CCL5; Poly I-C results in increased expression of CCL5 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; [TL8-506 co-treated with Poly I-C] results in increased expression of CCL5 mRNA; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of CCL5]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of CCL5]
Poly I-C results in increased expression of CD40 protein [Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein; [TL8-506 co-treated with Poly I-C] results in increased expression of CD40 mRNA
Poly I-C results in increased expression of CD83 protein CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of CD86 protein]
[Poly I-C co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of CDX2 mRNA; [Poly I-C co-treated with Tetrachlorodibenzodioxin] results in increased expression of CDX2 mRNA
Cannabidiol inhibits the reaction [Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]]; Poly I-C inhibits the reaction [Rimonabant binds to CNR1 protein]
Ethanol inhibits the reaction [Poly I-C results in increased expression of CSF2 protein] Poly I-C results in increased secretion of CSF2 protein [TL8-506 co-treated with Poly I-C] results in increased expression of CSF2 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of CSF2 protein; Smoke inhibits the reaction [Poly I-C results in increased secretion of CSF2 protein]
APPL1 protein promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; chrysin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of CXCL10 mRNA] Poly I-C results in increased secretion of CXCL10 protein cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA] Poly I-C results in increased expression of CXCL10 mRNA; Poly I-C results in increased expression of CXCL10 protein [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; [Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Cannabidiol inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Particulate Matter inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]; Phosphorothioate Oligonucleotides inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of CXCL10 protein]; Vehicle Emissions inhibits the reaction [[Pam(3)CSK(4) peptide co-treated with Antigens, Bacterial co-treated with Poly I-C co-treated with Lipopolysaccharides co-treated with FSL-1 lipoprotein, synthetic co-treated with Imiquimod co-treated with Polyribonucleotides co-treated with ProMune] results in increased expression of CXCL10 protein]
Ethanol inhibits the reaction [Poly I-C results in increased expression of CXCL1 protein] [TL8-506 co-treated with Poly I-C] results in increased secretion of CXCL1 protein
Luteolin inhibits the reaction [Poly I-C results in increased expression of CXCL9 mRNA]; methyldithiocarbamate inhibits the reaction [Poly I-C results in increased secretion of CXCL9 protein]
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT1 mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT1 mRNA
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in increased expression of DNMT3A mRNA; [Arsenicals co-treated with Poly I-C] results in increased expression of DNMT3A mRNA
[Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of EGR1 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR1 mRNA] Poly I-C affects the methylation of EGR1 promoter
Poly I-C results in increased expression of EIF2AK2 mRNA Poly I-C results in increased phosphorylation of EIF2AK2 protein EIF2AK2 results in increased susceptibility to Poly I-C
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; RTKI cpd inhibits the reaction [Poly I-C results in decreased expression of F11R protein]; SB 203580 inhibits the reaction [Poly I-C results in decreased expression of F11R protein]
Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Particulate Matter inhibits the reaction [Poly I-C results in increased expression of GZMB protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB mRNA]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of GZMB protein] Poly I-C results in increased expression of GZMB mRNA; Poly I-C results in increased expression of GZMB protein
Indoprofen inhibits the reaction [Poly I-C results in increased secretion of and affects the localization of HMGB1 protein]; Poly I-C results in increased secretion of and affects the localization of HMGB1 protein
[TL8-506 co-treated with Poly I-C] results in increased expression of FAM126A mRNA; [TL8-506 co-treated with Poly I-C] results in increased expression of HYCC1 mRNA
Poly I-C results in increased expression of IDO1 mRNA poly(I:C) co-treated with tryptophan or alone increases activity and expression of IDO1 protein in Langerhans cell-like dendritic cells
Poly I-C results in increased expression of IFIH1 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]
[TL8-506 co-treated with Poly I-C] results in increased expression of IFIT2 mRNA; Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of IFIT2 mRNA]
Poly I-C results in increased expression of IFNB1 mRNA; Poly I-C results in increased expression of IFNB1 protein Poly I-C results in increased secretion of IFNB1 protein MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] apilimod inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; APPL1 protein promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; BX795 inhibits the reaction [Poly I-C results in increased expression of IFNB1 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Progesterone inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Resveratrol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; trametinib promotes the reaction [Poly I-C results in increased expression of IFNB1 mRNA] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; [TL8-506 co-treated with Poly I-C] results in increased expression of IFNB1 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IFNB1 protein; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA; Cannabidiol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Dronabinol inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; Wortmannin inhibits the reaction [[Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of IFNB1 mRNA]
[Poly I-C co-treated with IFNG protein] results in increased secretion of CD40 protein; [Poly I-C co-treated with IFNG protein] results in increased secretion of CD86 protein; Smoke inhibits the reaction [Poly I-C results in increased expression of IFNG mRNA] Poly I-C results in increased secretion of IFNG protein Ethanol inhibits the reaction [Poly I-C results in increased expression of IFNG protein] Poly I-C results in increased expression of IFNG mRNA; Poly I-C results in increased expression of IFNG protein
IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein] Poly I-C results in decreased expression of IGF1 mRNA; Poly I-C results in decreased expression of IGF1 protein
[TL8-506 co-treated with Poly I-C] results in increased secretion of IL10 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein] Poly I-C results in increased expression of IL10 mRNA Poly I-C results in increased expression of IL10 mRNA; Poly I-C results in increased expression of IL10 protein Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL10 protein]
6-formylindolo(3,2-b)carbazole inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; [CL 075 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [resiquimod co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [TL8-506 co-treated with Poly I-C] results in increased expression of IL12A mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; indole-3-carbinol inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]; Poly I-C promotes the reaction [TL8-506 results in increased secretion of [IL12A protein binds to IL12B protein]]; Tetrachlorodibenzodioxin inhibits the reaction [Poly I-C results in increased expression of IL12A mRNA]
[[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; [CL 075 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [resiquimod co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; [TL8-506 co-treated with Poly I-C] results in increased expression of IL12B mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of [IL12A protein binds to IL12B protein]; Particulate Matter analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Poly I-C promotes the reaction [TL8-506 results in increased secretion of [IL12A protein binds to IL12B protein]]; Vehicle Emissions analog inhibits the reaction [Poly I-C results in increased expression of IL12B protein] Poly I-C results in increased expression of IL12B mRNA; Poly I-C results in increased expression of IL12B protein Ethanol inhibits the reaction [Poly I-C results in increased expression of IL12B protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL12B mRNA]
[TL8-506 co-treated with Poly I-C] results in increased expression of IL1A mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL1A protein
APPL1 protein inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of IL1B mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of IL1B protein]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA] Poly I-C results in increased secretion of IL1B protein 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Poly I-C results in increased expression of IL1B mRNA]; [TL8-506 co-treated with Poly I-C] results in increased expression of IL1B mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL1B protein; Estradiol promotes the reaction [Poly I-C results in increased expression of IL1B protein]; Tetrachlorodibenzodioxin promotes the reaction [Poly I-C results in increased expression of IL1B mRNA] Poly I-C results in increased expression of IL1B mRNA; Poly I-C results in increased expression of IL1B protein
[TL8-506 co-treated with Poly I-C] results in increased expression of IL23A mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL23A protein
Poly I-C results in increased expression of IL27 mRNA [TL8-506 co-treated with Poly I-C] results in increased secretion of IL27 protein Luteolin inhibits the reaction [Poly I-C results in increased expression of IL27 mRNA]
Poly I-C results in increased expression of IL33 protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Poly I-C results in increased expression of IL33 protein] 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of IL33 protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL33 protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL33 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; [Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; [Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprost; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone; [Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL4 protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Estradiol promotes the reaction [Poly I-C results in increased expression of IL4 protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CCL5 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Itraconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Ketoconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; luliconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Particulate Matter inhibits the reaction [Poly I-C results in increased secretion of IL4 protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Thromboxane B2]; Terbinafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased secretion of IL4 protein] IL4 protein results in increased susceptibility to Poly I-C
[TL8-506 co-treated with Poly I-C] results in increased expression of IL6 mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of IL6 protein; [Vehicle Emissions analog co-treated with Poly I-C] results in increased secretion of IL6 protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Particulate Matter promotes the reaction [Poly I-C results in increased expression of IL6]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; Smoke inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TRAF6 mutant form inhibits the reaction [Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]]; Vehicle Emissions analog promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; Vehicle Emissions promotes the reaction [Poly I-C results in increased expression of IL6] Poly I-C results in increased expression of IL6 mRNA; Poly I-C results in increased expression of IL6 protein Ethanol inhibits the reaction [Poly I-C results in increased expression of IL6 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGF1 protein]; IL6 protein affects the reaction [Poly I-C results in decreased expression of IGFBP3 protein]; IL6 protein affects the reaction [Poly I-C results in increased expression of PRL2B1 mRNA]; IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Luteolin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; pitavastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA] Poly I-C results in increased expression of IL6; Poly I-C results in increased expression of IL6 mRNA
Poly I-C results in increased phosphorylation of IRF3 protein Poly I-C affects the localization of IRF3 protein APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; BX795 inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; chrysin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; DNM2 protein promotes the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; eriodictyol inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Quercetin inhibits the reaction [Poly I-C results in increased expression of IRF3 mRNA]; Sodium Selenite inhibits the reaction [Poly I-C results in increased activity of IRF3 protein] [Dronabinol co-treated with Cannabidiol] inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; [Vehicle Emissions analog co-treated with Poly I-C] affects the localization of IRF3 protein; Cannabidiol inhibits the reaction [Poly I-C affects the localization of IRF3 protein]; Dronabinol inhibits the reaction [Poly I-C results in increased localization of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]
IRF7 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; IRF7 protein mutant form affects the reaction [Nicotine inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]]; IRF7 protein mutant form inhibits the reaction [Nicotine inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIH1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IFIT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of IRF9 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT2 mRNA]; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased secretion of IFNB1 protein]; Nicotine inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA] cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of IRF7 mRNA]
Poly I-C results in increased expression of ISG15 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of ISG15 mRNA]
Atorvastatin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA]
Poly I-C results in decreased phosphorylation of MAPK1 protein Poly I-C results in increased phosphorylation of MAPK1 protein Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK1 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK1 protein]
Poly I-C results in decreased phosphorylation of MAPK3 protein Poly I-C results in increased phosphorylation of MAPK3 protein Suramin inhibits the reaction [Poly I-C results in decreased phosphorylation of MAPK3 protein]; trametinib inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Poly I-C results in increased phosphorylation of MAPK3 protein]
[Poly I-C co-treated with HU 211] results in decreased expression of MBP mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of MBP mRNA
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of MIR152 mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of MIR152 mRNA
MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]]; Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]
MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein]
Poly I-C promotes the reaction [MSI1 protein results in increased expression of KLF4 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of MYC protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein]; Poly I-C promotes the reaction [MSI1 protein results in increased expression of SOX2 protein]
Poly I-C results in increased expression of MX1 mRNA Acetylcysteine inhibits the reaction [Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA]]; Dieldrin inhibits the reaction [Poly I-C results in increased expression of MX1 mRNA]
Poly I-C results in increased expression of NFKB1 mRNA [Ivermectin co-treated with Atorvastatin] inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Atorvastatin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Ivermectin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]
Poly I-C results in increased phosphorylation of NFKBIA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; [Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]
pitavastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of NOS2 protein] Diclofenac promotes the reaction [Poly I-C results in increased expression of NOS2 mRNA] Poly I-C results in increased expression of NOS2 mRNA; Poly I-C results in increased expression of NOS2 protein
Poly I-C results in increased expression of OAS1 mRNA [[Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein] which results in increased abundance of 2',5'-oligoadenylate; [Poly I-C co-treated with Interferon-alpha] results in increased activity of OAS1 protein; IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of OAS1 mRNA]
Poly I-C promotes the reaction [MSI1 protein results in increased expression of POU5F1 protein] Poly I-C results in increased expression of POU5F1 protein
Particulate Matter inhibits the reaction [Poly I-C results in increased expression of PRF1 protein]; Vehicle Emissions inhibits the reaction [Poly I-C results in increased expression of PRF1 protein] Poly I-C results in increased expression of PRF1 mRNA; Poly I-C results in increased expression of PRF1 protein
[Poly I-C co-treated with HU 211] results in decreased expression of PRKCI mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of PRKCI mRNA
Poly I-C results in increased expression of PTGS2 protein [Poly I-C results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] which results in increased expression of PTGS2 mRNA; Poly I-C promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of PTGS2 mRNA]; resveratrol inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein]; Sodium Selenite inhibits the reaction [Poly I-C results in increased expression of PTGS2 protein]
[Poly I-C co-treated with HU 211] results in decreased expression of RAC1 mRNA [Poly I-C co-treated with Atorvastatin] results in decreased expression of RAC1 mRNA; [Poly I-C co-treated with Ivermectin] results in decreased expression of RAC1 mRNA
[Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB mRNA; [Arsenicals co-treated with Poly I-C co-treated with Alitretinoin] results in decreased expression of RARB protein; [Arsenicals co-treated with Poly I-C] affects the expression of RARB mRNA; [Arsenicals co-treated with Poly I-C] results in decreased expression of RARB protein
Poly I-C affects the localization of RELA protein Poly I-C results in increased phosphorylation of RELA protein TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein]
[Poly I-C co-treated with Atorvastatin co-treated with Ivermectin] results in increased expression of RHOA mRNA; [Poly I-C co-treated with Atorvastatin] results in increased expression of RHOA mRNA
Poly I-C results in increased expression of RIGI mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of RIGI mRNA]
Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA] Poly I-C results in increased expression of SERPINE1 mRNA; Poly I-C results in increased expression of SERPINE1 protein
Poly I-C results in increased expression of SOCS1 mRNA [TL8-506 co-treated with Poly I-C] results in increased expression of SOCS1 mRNA Progesterone promotes the reaction [Poly I-C results in increased expression of SOCS1 mRNA]
sodium arsenite inhibits the reaction [Poly I-C results in increased phosphorylation of STAT1 protein] Poly I-C results in increased expression of STAT1 mRNA IRF7 protein mutant form inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]; Nicotine inhibits the reaction [Poly I-C results in increased expression of STAT1 mRNA]
IL6 protein affects the reaction [Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein]; Poly I-C results in increased phosphorylation of and results in increased activity of STAT3 protein
APPL1 protein promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein]
[[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of IL12B protein; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-aminopyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to 1-nitropyrene; [Poly I-C binds to TLR3 protein] which affects the susceptibility to pyrene; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 mRNA; [Vehicle Emissions analog co-treated with Poly I-C] results in increased expression of TLR3 protein; Chloroquine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; Poly I-C binds to and results in increased activity of TLR3 protein; Quinacrine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of IL6 mRNA]; TLR3 mRNA promotes the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TLR3 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA] MIR26A mRNA inhibits the reaction [Poly I-C results in increased activity of TLR3 protein] Poly I-C results in increased expression of TLR3 mRNA cinnamaldehyde inhibits the reaction [Poly I-C results in increased expression of TLR3 mRNA]
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane promotes the reaction [Poly I-C results in increased expression of TNF protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TNF protein]; [[Poly I-C binds to and results in increased activity of TLR3 protein] which co-treated with Nanotubes, Carbon] results in increased secretion of TNF protein; [TL8-506 co-treated with Poly I-C] results in increased expression of TNF mRNA; [TL8-506 co-treated with Poly I-C] results in increased secretion of TNF protein; CEP-11004 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; CpG ODN 2006 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TNF protein]; N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of TNF protein] Poly I-C results in increased expression of TNF mRNA; Poly I-C results in increased expression of TNF protein cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; MIR26A mRNA inhibits the reaction [Poly I-C results in increased expression of TNF protein] APPL1 protein inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Citrinin inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Ethanol inhibits the reaction [Poly I-C results in increased expression of TNF protein]; Ethanol inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Ethanol promotes the reaction [Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]]; Hydroxamic Acids analog inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Hydroxamic Acids analog promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]]; Luteolin inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of TNF mRNA]; sodium arsenite inhibits the reaction [Poly I-C results in increased expression of TNF mRNA]
TP53 protein affects the reaction [Poly I-C affects the localization of RELA protein]; TP53 protein affects the reaction [Poly I-C results in increased expression of CXCL8 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased expression of IFNB1 mRNA]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; TP53 protein affects the reaction [Poly I-C results in increased phosphorylation of NFKBIA protein]; TP53 results in increased susceptibility to [Poly I-C co-treated with Fluorouracil]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]]; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA; [Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Estradiol promotes the reaction [Poly I-C results in increased expression of TSLP protein]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; helenalin inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP mRNA]; IL4 protein promotes the reaction [Poly I-C results in increased expression of TSLP protein]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] Poly I-C results in increased expression of TSLP mRNA; Poly I-C results in increased expression of TSLP protein
P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]
[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; montelukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate metabolite results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]
IDH2 protein mutant form results in increased abundance of Uridine Diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Uridine Diphosphate]
MRS 2211 inhibits the reaction [Uridine Diphosphate results in increased expression of IL6 protein]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
Uridine Diphosphate results in increased phosphorylation of MAPK1 protein P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein]
Uridine Diphosphate results in increased phosphorylation of MAPK3 protein P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein]
P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of CXCL2 protein]]; P2RY6 gene affects the reaction [Uridine Diphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK1 protein]; P2RY6 gene mutant form inhibits the reaction [Uridine Diphosphate results in increased phosphorylation of MAPK3 protein] P2RY6 gene affects the susceptibility to Uridine Diphosphate
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]
B3GAT3 protein binds to Uridine Diphosphate Glucuronic Acid Uridine Diphosphate Glucuronic Acid inhibits the reaction [Diacetyl results in decreased activity of B3GAT3 protein]
[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; [Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased metabolism of hyodeoxycholic acid; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol]
[Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]
NF157 compound inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein] MRS 2211 inhibits the reaction [Uridine Triphosphate results in increased expression of IL6 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein] Uridine Triphosphate results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [Nicotinic Acids results in increased activity of HCAR2 protein] promotes the reaction [[Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids]; [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased abundance of Arachidonic Acids; Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein] Uridine Triphosphate results in increased phosphorylation of MAPK3 protein
Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein]
Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of MYL2 protein]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein]
Uridine Triphosphate inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYL2 protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]]; Uridine Triphosphate inhibits the reaction [MYOCD protein results in increased expression of NPPA protein]; Uridine Triphosphate inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] Uridine Triphosphate results in increased expression of NPPA mRNA
Uridine Triphosphate binds to and results in increased activity of P2RY2 protein Endocannabinoids inhibits the reaction [Uridine Triphosphate binds to and results in increased activity of P2RY2 protein]; Uridine Triphosphate binds to and results in increased activity of P2RY2 protein
ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Uridine Triphosphate results in increased activity of TRPC3 protein]
browse the term
